Americký regulátor NHTSA zahájil prověřování asi 1 000 vozů Tesla Cybercab kvůli tomu, jak firma prokazovala shodu s federálními bezpečnostními normami. Zkoumá i vozidla bez volantu, pedálů a zrcátek.
The U.S. National Highway Traffic Safety Administration said it has opened an audit into about 1,000 Tesla (TSLA.O) Cybercab vehicles, examining the process and technical data the EV maker relied on to claim compliance with federal vehicle safety standards.
The probe comes after Tesla on Thursday began commercial deployment of a small number of the two-seater Cybercab in Austin, Texas, and said it planned to gradually expand the service to additional vehicles and locations.
NHTSA said the Cybercab lacks permanently attached conventional manual controls, including a steering wheel, brake pedal, accelerator pedal and mirrors.
The agency said it would examine the basis for Tesla's certification and related issues, including the extent to which the company determined that certain Federal Motor Vehicle Safety Standards were not applicable to the vehicle.
Tesla did not immediately respond to a request for comment.
The EV maker had 420 autonomous vehicles registered in Texas as of Friday morning, according to state records, including 45 Cybercab vehicles.
lululemon snížil celoroční výhled tržeb i zisku po slabších výsledcích ve 2. čtvrtletí, kdy tržby klesly o 4 % a srovnatelné tržby o 9 %, a po poklesu prodejů v Číně. Akcie v premarketu klesají o 18 %.
Download this episode on Apple Podcasts/Spotify or listen below:
Another forecast trim, a China slowdown, and rising competition send lululemon (LULU) shares tumbling. (00:15) The robotaxi era begins with little fanfare as Tesla (TSLA) rolls out Cybercab rides in Austin. (01:49) Volkswagen (VWAGY) is preparing another 50,000 job cuts. (03:03)
This is an abridged transcript.
lululemon athletica (LULU) is a trending topic on Seeking Alpha.
LULU shares are underwater after the company cut its full-year sales guidance again and realized a much larger than expected decline in sales as China continues to disappoint and rivals gain ground in the U.S.
“While we continue to navigate some challenging dynamics, we are taking a prudent approach with our revised full-year outlook,” said Lululemon interim co-CEO Meghan Frank.
Although a new CEO is set to take over next week, lululemon (LULU) is expected to limp through the remainder of the year with another cut to sales guidance, now expected to contract by 5% to 7% to a range of $10.35B to $10.50B.
Moreover, the company now expects to earn a profit of $9.48 to $9.73 per share, down from between $10.95 to $11.15 per share and below the $10.93 per share estimate.
For the current quarter, net sales are expected to decline by 10% to 11%.
The downbeat outlook reflects second-quarter results in which revenue decreased 4% and comparable sales were down 9%, both of which were worse than expected.
Including an $0.86 per share benefit from tariff refunds, lululemon (LULU) earned a profit of $2.92 per share, down 6% year-over-year but better than expectations.
Shares are down 18% in premarket action.
Tesla (TSLA) will begin offering Cybercab rides in "limited areas" of Austin, Texas today, while its highly anticipated launch event ended on a fairly muted note.
There are 45 Cybercabs registered in Texas. The company did not include details on fares when they announced the launch on Thursday.
As for the event, there was no public livestream or journalists. The Verge reported that it had a very short invite list comprised largely of pro-Tesla (TSLA) content creators.
Attendees told Reuters that Elon Musk skipped the event. Executives discussed the Cybercab's manufacturing process and technology for about a quarter of an hour.
The golden two-seater vehicle is fully autonomous with no steering wheel or pedals, using camera vision and sensors for navigation. Tesla (TSLA) previously said the cost would be less than $30,000.
Children under the age of 13 are not permitted to ride in a Cybercab. Minors aged 13-17 can travel in a Cybercab if accompanied by an adult.
Shares of Tesla (TSLA) ended 5.4% higher on Thursday ahead of the Cybercab event, but are down 1.6% premarket.
Volkswagen AG (VWAGY) is getting rid of more people.
The company said on Thursday that its supervisory board has approved a wide-ranging restructuring program that includes a further reduction of 50,000 jobs.
The board voted unanimously on Thursday to endorse the company’s “Future Plan” for transforming the Volkswagen (VWAGY) Group and its brands. The program is intended to make the business more efficient and competitive and to better prepare it for the future.
The additional job cuts would take Volkswagen’s (VWAGY) expected workforce reduction to 100,000. The group also plans to cut the number of models it offers by around half by 2035 and reduce its holdings.
Volkswagen (VWAGY) said it would provide further details of the plan in the near future.
What’s Trending on Seeking Alpha:
What's shaping the geography of U.S. AI data centers?
Elon Musk’s super PAC spends $800K on key Republican midterm races
Oil trends toward biggest weekly gain since July; ING raises price forecast
Stock index futures are largely flat as investors focus on the upcoming jobs report.
Crude oil is down 0.5% at $90. Brent crude is down 0.4% at $95.
The FTSE 100 is little changed and the DAX is little changed.
Economic calendar:
8:30 am Employment Situation: The August jobs report is expected to show nonfarm payroll additions of 55,000 for the month, a 4.1% unemployment rate, and 3.0% year-over-year wage growth.
It is officially just 60 days before the U.S. midterm elections, which some analysts indicate is the beginning of the window when investment managers start making election-related portfolio changes.
Be sure to take the Seeking Alpha weekly news quiz.
Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.
Lemonade v Missouri spustila pojištění pro vozy Tesla s 50% slevou za každou autonomně ujetou míli s Full Self-Driving (Supervised). Firma říká, že cena vychází z dat o nižší nehodovosti.
Elon Musk said Tesla's self-driving tech could save your life. Now one insurer has looked at the crash data and decided to put real money behind that claim, and the number they landed on is turning heads across the industry.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
On August 30, Elon Musk told his followers on X: “Try Tesla self-driving. It will improve your quality of life and may save your life.” Three days later, the company that would actually cut the checks when a Tesla crashes put a number on that claim.
Lemonade (NYSE:LMND) launched Lemonade Car and Lemonade Autonomous Car in Missouri on September 2, 2026, offering Tesla drivers 50% off every mile driven using Full Self-Driving (Supervised). The discount applies only to autonomous miles, with human-driven segments priced at standard rates.
President and Co-Founder Shai Wininger called the dual product debut “a first for us,” and framed the discount as underwriting math: “Tesla’s safe FSD (Supervised) tech reduces the chances of getting into an accident. Our intelligent pricing models see this in the data and can pass real savings, with high precision, on to Tesla customers, right from the start.”
Actuarial Table Meets Autopilot I’ve been watching Lemonade for years, and this is the first time I’ve seen a carrier publicly grade a founder’s safety pitch in dollars. On the Q2 call, management said the discount is not a marketing round number: “The 50% number that we’ve quoted is really our number data driven through the data that we’ve analyzed as we put that product together.” They added that “the public numbers we’re seeing are that amount of savings or greater.”
The autonomous product rolled out in Colorado and Indiana before Missouri. Lemonade said the autonomous variant is launching with ~70% higher new customer conversion rates vs comparable non-autonomous product.
Rapid State Expansion Missouri is the third state announcement in barely a week. Lemonade launched car insurance in Florida on August 26 and expanded renters into Kansas on September 1. Car insurance in-force premium hit $239M in Q2 2026, up from $239M in Q2 2026, up from $239M in Q2 2026, up from $239M in Q2 2026, up from $150M50M50M50M a year earlier.
CEO Daniel Schreiber describes the pricing engine as “some 50” machine-learning algorithms working in concert. Q2 revenue rose 79.4% to $294.4M, and the LAE ratio hit 5%, versus an industry average around 9%. Schreiber told analysts: “That kind of structural advantage allows us to produce a pricing advantage that will allow us to continue to grow and take market share.”
Stock Doesn’t Believe It Yet Shares have lagged. LMND closed at $51.34 on September 1, down 28% year to date, then popped 3.4% on September 2. Schreiber has staked his credibility on a date: “We steadily progress towards our first Adj. EBITDA positive quarter, which we continue to expect in Q4 2026.”
If FSD miles really do crash half as often, Lemonade gets to price the road ahead before legacy carriers even reprice yesterday. If the model misfires, Lemonade is the one writing the check. Musk made the pitch. Lemonade just made it a line item.
Contact [email protected] for any questions or corrections.
Cathie Wood has spent years backing challengers to dominant technology companies, but her latest semiconductor move leaned firmly towards the market leader.
ARK Invest sold about $72.8 million of AMD shares in its August 28 trades while buying roughly $53 million of Nvidia stock.
AMD disposal was valued at about $74.5 million and the Nvidia purchase at $55.6 million.
The move came days after Nvidia delivered another blockbuster quarter. But ARK has not said the trade reflects a loss of confidence in AMD.
The more defensible reading is that Wood was rotating towards clearer near-term AI earnings visibility.
Nvidia had just reported fiscal second-quarter revenue of $96.2 billion, up 106% from a year earlier, while Data Center revenue jumped 117% to $89 billion. The company guided for roughly $108 billion of revenue next quarter.
Nvidia is no longer asking investors to wait several product cycles for its AI thesis to show up in financial results.
Demand is already translating into enormous revenue, and management says supply remains a constraint.
TD Cowen analyst Joshua Buchalter described Nvidia shares as “materially undervalued” after the results, according to MarketWatch. He argued that without supply constraints, customer demand could point to revenue nearly doubling.
Bank of America analyst Vivek Arya made a similar valuation case before earnings.
Arya saw Nvidia stock trading at a 34% to 50% discount to what its fundamentals could justify while maintaining a $350 target.
For ARK, that combination of dominant market position and visible earnings growth may have made Nvidia the more attractive destination for incremental chip exposure.
AMD’s own numbers hardly suggest a broken story.
Second-quarter revenue reached a record $11.5 billion, up 50% year on year, while Data Center revenue more than doubled.
Chief executive Lisa Su said Helios, AMD’s rack-scale AI platform, was beginning to ramp in the second half.
The difference is that investors are still waiting to see how quickly Helios can translate into a much larger AI revenue stream.
Futurum Group chief executive Daniel Newman captured that tension after AMD’s results.
Yahoo Finance reported that Newman viewed the quarter as good, but said investors had been looking for a much stronger guide driven by Helios.
Wall Street remains constructive on AMD.
Goldman Sachs upgraded the stock to Buy in May, arguing that AMD could be an outsized beneficiary of enterprise agentic AI adoption as demand supports both server CPUs and future data-centre GPU growth.
The firm also said it continued to prefer Nvidia and Broadcom on a relative basis.
That last point fits ARK’s August 28 activity especially well, as Wood did not simply sell AMD and buy Nvidia. ARK also added roughly $20 million of Broadcom stock.
That looks more like a reshaping of semiconductor exposure across several AI winners than a binary call that AMD has lost.
Your employer's 401(k) plan could soon have a brand-new, never-before-offered kind of investment option -- funds that hold a healthy dose of privately owned (as opposed to publicly traded) businesses.
That's the important takeaway from an announcement by investment manager BlackRock (BLK +1.72%) around the middle of this year. As the stock market's risks rise and its rewards shrink -- and as it grows more difficult to navigate -- BlackRock wants to give ordinary investors access to potentially better returns.
Here's what you need to know.
The how and why Your retirement savings account's exposure to privately held businesses will still be relatively limited, for the record. Initially, only target-date mutual funds overseen by Great Gray Trust will hold stakes in these enterprises, and even then, only 5% to 20% of these funds' capital will be allocated to private investments. And investors will only be able to access this narrow selection of target-date funds if their 401(k) plan's sponsor and administrator agree that adding this option is in employees' best interest.
Image source: Getty Images.
It shouldn't be terribly difficult to sell this idea to sponsors and administrators, however. BlackRock (which manages the iShares family of exchange-traded funds) notes that, on average, privately owned ventures return about 50 more basis points annually than stocks. Over the course of 40 years, that would make 401(k) account balances about 15% bigger than they'd otherwise be using nothing but conventional stock-based funds.
Demand is growing Although this launch will be one of the first of its kind for 401(k) plans, access to private enterprises through publicly traded instruments is not unheard of. Business development companies like Main Street Capital (MAIN +0.35%) are a form of private equity and private credit, while Brookfield Asset Management's (BAM +1.25%) Brookfield Renewable Partners (BEP +0.23%) (BEPC +0.38%) offers its shareholders exposure to a basket of energy-related ventures that aren't accessible any other way. Hedge fund manager Bill Ackman is also planning a new venture fund that will offer ordinary, non-institutional investors access to companies that have not yet gone public, but eventually will.
Still, these options remain relatively rare.
That's clearly changing, though. Perhaps finally prompted by the recent initial public offering of Space Exploration Technologies -- you know it better as SpaceX -- which has made its earliest insiders considerably wealthier than its post-IPO investors, more people are clamoring for alternatives capable of delivering better returns. BlackRock's and Great Gray's offering will certainly bring that prospect to the table.
That said, it would also be naïve to ignore the fact that the stock market as a whole has become uncomfortably unbalanced. The S&P 500's 10 biggest companies collectively account for nearly 40% of its value, while nearly as much of the index's value is held by technology stocks. If only for the sake of better diversification, access to alternative investments (private or otherwise) have their obvious appeal.
Look for more of the same Only time will tell how quickly BlackRock's concept becomes a common option for 401(k) plans. Don't be surprised to see measurable interest, though. In this same vein, don't be surprised to see other outfits introduce similar private investment offerings now that BlackRock is pushing the boundaries of the premise.
James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BlackRock and Brookfield Asset Management. The Motley Fool recommends Brookfield Renewable and Brookfield Renewable Partners. The Motley Fool has a disclosure policy.
Allen Mooney & Barnes Investment Advisors LLC ve 2. čtvrtletí snížila podíl ve společnosti Lowe’s o 6,6 % a prodala 4 362 akcií. Po transakci držela 61 811 akcií na hodnotu 13,629 milionu USD.
Allen Mooney & Barnes Investment Advisors LLC decreased its holdings in Lowe’s Companies, Inc. (NYSE:LOW – Free Report) by 6.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,811 shares of the home improvement retailer’s stock after selling 4,362 shares during the quarter. Lowe’s Companies comprises 2.1% of Allen Mooney & Barnes Investment Advisors LLC’s investment portfolio, making the stock its 19th largest holding. Allen Mooney & Barnes Investment Advisors LLC’s holdings in Lowe’s Companies were worth $13,629,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Norges Bank acquired a new position in Lowe’s Companies in the 4th quarter valued at $1,993,697,000. Price T Rowe Associates Inc. MD boosted its holdings in Lowe’s Companies by 45.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,555,565 shares of the home improvement retailer’s stock valued at $1,580,941,000 after purchasing an additional 2,039,343 shares in the last quarter. J. Stern & Co. LLP increased its position in Lowe’s Companies by 7,814.9% during the 4th quarter. J. Stern & Co. LLP now owns 1,490,369 shares of the home improvement retailer’s stock worth $359,417,000 after purchasing an additional 1,471,539 shares during the period. Eurizon Capital SGR S.p.A. acquired a new position in Lowe’s Companies during the 4th quarter worth approximately $308,683,000. Finally, Viking Global Investors LP purchased a new position in shares of Lowe’s Companies during the 4th quarter worth approximately $219,948,000. Institutional investors and hedge funds own 74.06% of the company’s stock.
Wall Street Analysts Forecast Growth LOW has been the topic of a number of analyst reports. Weiss Ratings downgraded Lowe’s Companies from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 17th. UBS Group dropped their price target on Lowe’s Companies from $285.00 to $275.00 and set a “buy” rating for the company in a research report on Thursday, August 20th. Truist Financial decreased their price objective on shares of Lowe’s Companies from $255.00 to $254.00 and set a “buy” rating on the stock in a research report on Thursday, August 20th. Bank of America dropped their target price on shares of Lowe’s Companies from $260.00 to $257.00 and set a “neutral” rating for the company in a report on Thursday, May 21st. Finally, Benchmark assumed coverage on shares of Lowe’s Companies in a research report on Tuesday, May 12th. They set a “hold” rating for the company. Twenty-three equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $258.53.
Read Our Latest Research Report on Lowe’s Companies Lowe’s Companies Trading Up 1.1% Shares of LOW stock opened at $202.09 on Friday. The firm has a 50-day moving average price of $213.80 and a 200 day moving average price of $228.09. Lowe’s Companies, Inc. has a twelve month low of $199.34 and a twelve month high of $293.06. The company has a market capitalization of $113.38 billion, a price-to-earnings ratio of 17.08, a PEG ratio of 2.66 and a beta of 0.85.
Lowe’s Companies (NYSE:LOW – Get Free Report) last released its earnings results on Wednesday, August 19th. The home improvement retailer reported $4.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.22 by $0.18. Lowe’s Companies had a net margin of 7.34% and a negative return on equity of 75.67%. The company had revenue of $25.96 billion for the quarter, compared to analyst estimates of $26.13 billion. During the same period in the prior year, the firm earned $4.33 EPS. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. Lowe’s Companies has set its FY 2026 guidance at 12.250-12.250 EPS. As a group, research analysts predict that Lowe’s Companies, Inc. will post 12.26 earnings per share for the current year.
Lowe’s Companies Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 4th. Investors of record on Wednesday, October 21st will be given a dividend of $1.25 per share. The ex-dividend date of this dividend is Wednesday, October 21st. This represents a $5.00 annualized dividend and a yield of 2.5%. Lowe’s Companies’s dividend payout ratio is 42.27%.
Insiders Place Their Bets In other news, EVP Janice Dupré sold 14,150 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $221.90, for a total transaction of $3,139,885.00. Following the completion of the sale, the executive vice president directly owned 39,785 shares of the company’s stock, valued at $8,828,291.50. The trade was a 26.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Juliette Pryor sold 9,330 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $224.81, for a total value of $2,097,477.30. Following the sale, the executive vice president owned 16,142 shares of the company’s stock, valued at approximately $3,628,883.02. The trade was a 36.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 25,980 shares of company stock valued at $5,796,937 over the last quarter. Company insiders own 0.29% of the company’s stock.
Trending Headlines about Lowe’s Companies Here are the key news stories impacting Lowe’s Companies this week:
Positive Sentiment: Lowe’s Foundation launched the “Building Futures Skilled Trades Coalition,” bringing together NVIDIA, AT&T, Bank of America, General Motors, Carrier, DEWALT and Duke Energy to help train one million skilled-trades workers by 2035. The initiative could strengthen Lowe’s long-term customer and labor pipeline while supporting demand for home-improvement projects. Nvidia Is Now Paying to Train Plumbers, and the Stock That Should Benefit Most Just Hit a 52-Week Low Neutral Sentiment: Lowe’s kicked off the second year of its “Earn Your Sunday” NFL campaign, adding Myles Garrett and Jordan Love to its roster of football ambassadors. The marketing effort may increase brand engagement and project-related traffic, but its direct earnings impact is uncertain. Lowe’s Kicks Off Year Two of Earn Your Sunday Neutral Sentiment: A comparison of Lowe’s and Home Depot dividends highlighted concerns about dividend coverage and the pace of future increases for at least one retailer. The report could make income-focused investors more cautious, although the provided details do not clearly identify Lowe’s as the company with the weaker coverage. Home Depot vs. Lowe’s: One Dividend Looks Much Stronger Under the Hood Negative Sentiment: Mortgage rates reached a one-year high following a global bond-market sell-off. Higher financing costs can reduce housing activity and delay big-ticket renovations, pressuring sales at Lowe’s and Home Depot. Mortgage Rates Just Hit a 1-Year High Negative Sentiment: Zacks Research reduced several Lowe’s earnings forecasts, including FY2027 EPS to $12.25 from $12.45, FY2028 to $12.94 from $13.60 and FY2029 to $13.90 from $14.62. Although one later-quarter estimate increased slightly, the broad downward revisions signal weaker expected profit growth and are likely weighing on the stock. Lowe’s Companies Analyst Estimates Lowe’s Companies Profile (Free Report)
Lowe’s Companies, Inc is a leading home improvement retailer that operates large-format stores and digital channels serving both do-it-yourself homeowners and professional contractors. The company offers a broad assortment of products including building materials, lumber, appliances, tools and hardware, plumbing and electrical supplies, paint, flooring, kitchen and bath fixtures, outdoor and garden products, and home decor. Lowe’s also provides a range of services such as installation, home improvement financing, tool and equipment rental, and contractor-focused sales programs.
Operations are centered on a nationwide brick-and-mortar store network supported by distribution centers and an e-commerce platform that enables online ordering, delivery and in-store pickup.
Featured Stories Five stocks we like better than Lowe’s Companies The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now Dropping the Dough: Yum! Brands Strategically Trims the Fat These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern Want to see what other hedge funds are holding LOW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lowe’s Companies, Inc. (NYSE:LOW – Free Report).
Receive News & Ratings for Lowe's Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lowe's Companies and related companies with MarketBeat.com's FREE daily email newsletter.
Con Edison prodloužila sérii růstu dividend na 52. rok v řadě, což je nejdelší potvrzená série na tomto seznamu. Duke Energy a Southern Company také vykazují více než 20 let každoročního zvyšování dividend, přičemž Southern Company zvyšuje dividendu každý rok od roku 2010.
Not every dividend stock survives a recession with its payout intact, but regulated utilities operate under a different set of rules entirely. These three have raised dividends for decades by design, and the mechanics behind that streak are worth understanding…
Regulated electric utilities are one of the few places income investors can find dividends backed by cash flows that don’t rely on the economic cycle. Rate cases, riders, and long-term customer contracts turn capital spending into recoverable revenue, which is why payouts at these three names have kept climbing for decades. The clearest example: Con Edison’s “50 straight years of dividend increases, a record unmatched among utilities in the S&P 500” was extended again this year to a 52nd consecutive annual increase. Here are three regulated-cash-flow utilities that income-focused portfolios can lean on.
Duke Energy Duke Energy (NYSE:DUK | DUK Price Prediction) is one of the largest fully regulated electric utilities in the country, serving roughly 8.73 million retail customers across the Carolinas, Florida, Indiana, Ohio, and Kentucky, plus Piedmont Natural Gas. The stock closed at $121.40 on September 3, 2026, with an annualized forward dividend of $4.34 after the July step-up to a $1.085 quarterly rate.
On dividend safety, Duke’s coverage is anchored by an earnings base that grew through Q2. Adjusted EPS came in at $1.43 versus a $1.31 estimate, the fifth straight beat, and management reaffirmed full-year 2026 adjusted EPS guidance of $6.55 to $6.80 against a payout that runs at $4.34 annualized. Behind that, CFO Brian Savoy said Duke is tracking to a 14.5% FFO-to-debt target for 2026 with a longer-term expectation of 15%, describing the balance sheet as having “substantial cushion to our downgrade thresholds.” The dividend track record is equally sturdy: on the Q2 call, management noted “over 20 years of consecutive annual dividend increases” and framed the recent 2% raise as “consistent with growth in recent years.”
Duke is deploying more than $1 billion per month in regulated capital, has secured 7.8 gigawatts of data-center electric service agreements, and expects 5% to 7% long-term EPS growth through 2030, in the top half of the range beginning in 2028. Rate-case outcomes like the 9.8% allowed ROE with a 53% equity structure in North Carolina convert that spend into recoverable earnings.
Here’s the risk: Duke’s plan hinges on the timing of large-load ramps. Higher depreciation on the growing rate base, higher interest expense, and potential data-center load underperformance could delay the earnings acceleration that funds bigger dividend hikes.
Southern Company Southern Company (NYSE:SO) is the Southeast income anchor, operating Alabama Power, Georgia Power, Mississippi Power, Southern Power, and Southern Company Gas across roughly 9 million regulated utility customers. Shares finished at $88.77 on September 3, 2026, and the annualized forward dividend is $3.04 following the increase to a $0.76 quarterly payment.
Dividend safety at Southern is a function of geography and regulatory design. Q2 adjusted EPS was $1.13 versus a $1.00 estimate, and first-half adjusted EPS reached $2.46 with full-year 2026 adjusted EPS projected near or at the top of the $4.50 to $4.60 range. That earnings power sits well above the $3.04 payout. The dividend history is likewise consistent: the dividend record shows annual increases in the quarterly rate every year from 2010 through 2026, moving from $0.455 up to the current $0.76. Financing is disciplined too: Southern said its objective is to move toward 17% FFO to debt by 2029 and has already reduced its projected remaining equity need by 2030 to $1.1 billion.
Southern’s contracted large-load commitments now exceed 17 gigawatts by the mid-2030s, including a 3.2 gigawatt, 25-year electric service contract with OpenAI for a site near Savannah. Crucially for regulated cash flow, CEO Chris Womack said “Large load customers are paying their full share” and pricing includes minimum bills covering at least 100% of the incremental cost to serve, termination payments, and significant high-credit-quality collateral requirements. Retail base rates are held stable in Georgia and Alabama until 2029, insulating existing customers.
The risk to this thesis is that Southern Power’s wind-repowering hit continues to weigh on results, with roughly $205 million of accelerated depreciation remaining in 2026 and $120 million in 2027. Tariff and supply-chain pressures on the large capex plan are a related concern.
Consolidated Edison Consolidated Edison (NYSE:ED) is the New York regulated pure-play, running CECONY in NYC and Westchester, Orange and Rockland Utilities, and Con Edison Transmission. Shares closed at $108.75 on September 3, 2026, with an annualized forward dividend of $3.55 after the current $0.8875 quarterly rate took effect.
On safety, Con Edison has the longest verified dividend track record on this list: the Q2 release confirmed the 52nd consecutive year of dividend increases with a 4.4% annualized increase in 2026, a Dividend King streak visible in the payment record climbing from $0.535 in 1999 to $0.8875 in 2026 with no decreases. Q2 adjusted EPS was $0.83 versus a $0.77 estimate, and management reaffirmed full-year 2026 adjusted EPS guidance of $6.00 to $6.20. The balance sheet is straightforward: “We have no long-term parent company debt and prefer to raise debt capital at the operating companies where infrastructure investments are made.” Revenue visibility gets an additional boost from revenue decoupling in both gas and electric in New York State, which cushions earnings against volume swings.
Con Edison expects a regulated investment base 8.8% five-year CAGR from $46.4 billion in 2025 to roughly $67.2 billion by 2030, with capex rising from $6.6 billion in 2026 to $8.6 billion by 2030. CEO Tim Cawley pointed to 20% to 25% higher electric demand from new NYC buildings and 28 new substations by 2035, and framed the company as a “bellwether holding for any equity or debt investor seeking a steady and reliable investment.”
In terms of the risk: funding that capex requires meaningful equity issuance. Con Edison entered a $2.0 billion ATM equity offering program in May 2026 and plans up to $1.1 billion common equity plus $3.2 billion long-term debt issuance in 2026, and there is a Moody’s negative outlook on Con Edison and CECONY to watch.
Bringing It Together Duke, Southern, and Con Edison all share the same core dividend engine: state-regulated utilities that recover capital investment through rate cases and riders, and that are now leveraging data-center and electrification demand into multi-year rate-base growth. Duke offers the largest regulated capital plan and the freshest earnings acceleration story, Southern layers in contracted large-load revenue plus rate stability through 2029, and Con Edison brings the deepest dividend track record on the board with a 52-year streak of raises (we ranked ten more 50-year raisers by valuation in a free Dividend Kings report). For retirement-focused income, that is what durable payout support looks like.
Contact [email protected] for any questions or corrections.
Pratt & Whitney investuje 25 milionů USD do rozšíření závodu v Niepołomicích v Polsku, aby zvýšila kapacitu výroby dílů pro komerční i vojenské motory. Projekt má přinést více než 120 pracovních míst a spustit provoz v roce 2028.
Site will add more than 120 jobs and increase production capacity for commercial and military engine components
, /PRNewswire/ -- Pratt & Whitney, an RTX (NYSE: RTX) business, is investing $25 million (PLN 95 million) to expand its manufacturing facility in Niepołomice, Poland, which is dedicated to producing complex tubular assemblies for commercial and military engines. The expanded site is expected to become operational in 2028 creating more than 120 jobs and will help meet growing demand for commercial and military engines.
The Niepołomice facility already provides precision components for multiple engine types, including the Pratt & Whitney GTF™ engine powering commercial passenger aircraft, the PW800 powering business jets and the F135 powering all variants of the F-35 Lightning II fighter aircraft.
"Poland plays a vital role as a key hub in Pratt & Whitney's global engine production, a commitment further strengthened by our $125 million investment in facilities this year," said Dariusz Stopa, general manager, Pratt & Whitney in Niepołomice. "Our employees in Niepołomice manufacture high-precision engine components that support commercial and military aircraft around the world. Growing this team will increase our ability to meet global demand for advanced aircraft engines."
The investment is supported by the Polish government through the Polish Investment Zone Programme. The site's growth complements the recently announced $100 million investment in Pratt & Whitney's facilities in Rzeszow, Poland, which is also increasing production capacity and adding advanced capabilities for processing isothermally forged parts for the GTF, F135 and F100 engines.
Poland represents RTX's largest investment and employee base outside the United States, with more than 9,500 employees across its Collins Aerospace, Pratt & Whitney and Raytheon businesses in-country. Pratt & Whitney's sites in Poland provide advanced manufacturing and technology development capabilities for commercial and military engines, turboprops and auxiliary power units. This includes the manufacture of complex engine components such as the GTF fan drive gear system, F100 static structures and critical F135 parts.
About Pratt & Whitney
Pratt & Whitney, an RTX business, is a world leader in the design, manufacture and service of aircraft engines and auxiliary power units for military, commercial and civil aviation customers. Since 1925, our engineers have pioneered the development of revolutionary aircraft propulsion technologies, and today we support more than 90,000 in-service engines through our global network of maintenance, repair and overhaul facilities.
About RTX
With more than 180,000 global employees, we push the limits of technology and science to redefine how we connect and protect our world. With industry-leading capabilities, we advance aviation, engineer integrated defence systems for operational success, and develop next-generation technology solutions and manufacturing to help global customers address their most critical challenges. The company, with 2025 sales of more than $88 billion, is headquartered in Arlington, Virginia.
For questions or to schedule an interview, please contact [email protected].
Palo Alto Networks letos vzrostla o 78 % a výrazně překonává S&P 500 i Nasdaq-100. Tržby ve 4. čtvrtletí fiskálního roku 2026 stouply na 3,41 miliardy USD.
Palo Alto Networks (PANW +1.05%) is the world's largest cybersecurity company. Its stock has exploded by 78% in 2026 (as of the market close on Wednesday, Sept. 2), so it's obliterating the S&P 500 (^GSPC +1.06%) and Nasdaq-100 indexes, which have returned 12% and 15.4%, respectively.
Businesses are deploying artificial intelligence (AI) software at a rapid pace, leaving their sensitive data and valuable digital assets vulnerable to cyber attacks. Plus, hackers are using AI themselves to uncover holes in corporate defenses. These challenges call for highly advanced cybersecurity solutions, and that's exactly what Palo Alto Networks provides for its enterprise customers.
But here's why investors might want to think twice about buying Palo Alto stock following its blistering gain this year.
Image source: Getty Images.
Cybersecurity for the AI era AI agents can be configured to autonomously complete tasks without the need for further prompts from their human supervisors. This is a game-changer for productivity within the enterprise, but it also creates substantial risks because agents are constantly roaming through networks, data, and applications to complete their assigned tasks, often with minimal oversight.
Moreover, businesses are building agents and other AI software by using a range of different open-source models, which they pair with their internal data to achieve the best results. Willingly plugging sensitive information into any third-party application immediately leaves the enterprise vulnerable to a breach.
Simply put, many of the potential risks posed by AI are entirely self-inflicted, so Palo Alto is working hard to make sure enterprises can protect themselves.
The company's Prisma AIRS platform, for example, monitors every AI agent's actions in real time, while continuously scanning third-party models for vulnerabilities. It basically serves as a gateway for all AI-related traffic, ensuring that malicious applications don't infiltrate the enterprise. Prisma AIRS surpassed $100 million in annual recurring revenue during Palo Alto's fiscal 2026 fourth quarter (ended July 31), a mere 12 months after it launched, making it the fastest-growing product in the company's history.
But external threats still require significant attention. Earlier this year, Palo Alto's Unit 42 division demonstrated how an AI-driven attack can breach a corporate network in under 30 minutes, which is where the company's Cortex XSIAM product comes in. It's an AI-powered security operations platform that automates threat detection and incident remediation processes. It reduces the average customer's median time to respond to under 10 minutes, from days or even weeks previously.
Accelerating revenue growth A unified approach to cybersecurity is essential in the AI era. Products have to work together seamlessly and in real time to minimize vulnerabilities. This is driving a shift toward "platformization," which involves enterprises consolidating all of their cybersecurity spending with one vendor, and Palo Alto is quickly becoming one of the industry's top choices.
Palo Alto generated $3.41 billion in total revenue during the fiscal 2026 fourth quarter, a 34% increase from the year-ago period. That growth rate marked an acceleration from 31% in the third quarter just three months earlier, and platformizations were a key source of the momentum.
Premium Feature
Moneyball Superscore
92/100
Today's Change
(
1.05
%) $
3.46
Current Price
$
331.94
At the end of the quarter, Palo Alto had 2,500 platformed customers, which was a whopping 78% jump from the year-ago period. Plus, those customers had a net revenue retention rate of over 120%, meaning they had increased their spending by 20% compared to the same quarter last year.
Platformized customers are also the biggest buyers of Palo Alto's next-generation security (NGS) portfolio, which includes AI products like Prisma AIRS and XSIAM. ARR from the NGS portfolio soared by 63% year over year to $9 billion during the fourth quarter, but Palo Alto believes it can grow that figure to $20 billion from 4,000 platformized customers by fiscal 2030.
Palo Alto's valuation could limit further gains for shareholders Following its blistering gains in 2026, Palo Alto stock now trades at a price-to-sales (P/S) ratio of 21.7, which is twice its average dating back to its initial public offering (IPO) in 2012.
PANW PS Ratio data by YCharts
Moreover, Palo Alto is now 3.5 times as expensive as the Nasdaq-100 index, which has a P/S ratio of 6.1. In other words, it looks significantly overvalued compared to a basket of America's top technology companies.
Although Palo Alto has significant long-term growth potential based on management's fiscal 2030 forecast for platformizations and NGS ARR, investors are pricing in a lot of that growth right now, leaving very little room for further upside in its stock over the next few years. As a result, investors might want to wait for a pullback before jumping in -- if its P/S ratio falls back in line with its long-term average, that might be a good buying opportunity.
TJX po výsledcích za 2. čtvrtletí a snížení doporučení od dvou analytiků klesla za minulý měsíc téměř o 15 %. Firma sice zvýšila celoroční výhled zisku, ale stále je pod odhadem trhu.
TJX Companies (TJX +0.67%) had a rough time in late summer, at least as far as its stock was concerned. The company, best known for operating the TJ Maxx and Marshalls chains of discount department stores, released its latest quarterly earnings report, and investors found it dispiriting.
So too did several analysts, with two going so far as to downgrade their recommendations on the retailer. This combination of factors drove TJX's stock down by almost 15% last month.
Image source: Getty Images.
Not good enough for Mr. Market TJX reported its fiscal 2027 second-quarter figures on Aug. 19, revealing that total net sales were just under $15.2 billion, up 5% year over year. That was on the back of comparable sales growth of 4% across all of the company's divisions (which comprises the Marmaxx unit of TJMaxx and Marshalls, plus the HomeGoods brand and operations in Canada and overseas).
In terms of profitability, TJX also posted improvements. Net income under generally accepted accounting principles (GAAP) climbed by a robust 22% to $1.52 billion. On a non-GAAP (adjusted), per-share basis, that line item rose by 11% to $1.22.
Neither metric was far from its corresponding consensus analyst estimate. Revenue was basically in line with the average prognosticator projection, while the company's adjusted net profit was slightly above the collective expectation of $1.19.
Those trailing numbers didn't keep investors up at night, but stocks trade on future potential, not past results -- and that was the issue with this earnings report.
This, even though TJX actually raised its bottom-line guidance for the entirety of 2027 -- and for the second time in a row. Adjusted net income for the year is now expected to be $5.15 to $5.20 per share, up from the previous forecast of $5.08 to $5.15. It left its "comps" guidance intact at 3% to 4%. It added that it aims to increase its store count by 4% in fiscal 2028.
Yet the increased profitability range still sits under the average analyst estimate of $5.22 per share for the year. Investors can be rather unforgiving of companies that fall even an inch short of forward projections.
Premium Feature
Moneyball Superscore
73/100
Today's Change
(
0.67
%) $
0.88
Current Price
$
132.19
A pair of downgrades So can analysts. Several professional TJX trackers lowered their price targets on the stock in the wake of the earnings release.
Two of them took the additional step of downgrading their TJX recommendations. Jefferies' Corey Tarlowe reduced his to hold from buy, while Gordon Haskett's Chuck Grom changed his from buy to accumulate (a midpoint between buy and hold). This had the expected negative effect of dampening sentiment on the retailer's stock.
TJX had done well in previous quarters, so this latest one looked weak in comparison. Unfortunately, the preceding frames have helped crank up its stock price, so now it appears a bit expensive on valuation grounds. I'm not down on the company, which isn't doing badly at all, but I'd be hesitant to buy the stock at its current level.
BlackRock Inc. purchased a new position in shares of Yum China (NYSE:YUMC – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 442,625 shares of the company’s stock, valued at approximately $18,090,000. BlackRock Inc. owned about 0.13% of Yum China as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Ashoka WhiteOak Capital Pte Ltd boosted its position in Yum China by 0.7% during the fourth quarter. Ashoka WhiteOak Capital Pte Ltd now owns 28,350 shares of the company’s stock worth $1,342,000 after purchasing an additional 200 shares during the period. Glenview Trust Co raised its position in shares of Yum China by 4.3% in the fourth quarter. Glenview Trust Co now owns 4,904 shares of the company’s stock valued at $234,000 after purchasing an additional 200 shares during the period. Truist Financial Corp lifted its stake in shares of Yum China by 0.3% during the 4th quarter. Truist Financial Corp now owns 68,009 shares of the company’s stock worth $3,247,000 after buying an additional 211 shares during the last quarter. Biltmore Family Office LLC boosted its holdings in shares of Yum China by 3.1% during the 4th quarter. Biltmore Family Office LLC now owns 7,111 shares of the company’s stock worth $339,000 after buying an additional 216 shares during the period. Finally, Williams Jones Wealth Management LLC. boosted its holdings in shares of Yum China by 2.7% during the 4th quarter. Williams Jones Wealth Management LLC. now owns 8,258 shares of the company’s stock worth $394,000 after buying an additional 221 shares during the period. Institutional investors own 85.58% of the company’s stock.
Yum China Stock Performance NYSE:YUMC opened at $43.71 on Friday. Yum China has a twelve month low of $40.15 and a twelve month high of $58.39. The company has a quick ratio of 0.78, a current ratio of 0.96 and a debt-to-equity ratio of 0.01. The stock’s 50-day simple moving average is $45.13 and its 200 day simple moving average is $47.25. The firm has a market capitalization of $14.97 billion, a PE ratio of 16.01, a price-to-earnings-growth ratio of 1.18 and a beta of 0.08.
Yum China (NYSE:YUMC – Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.67 by $0.03. The firm had revenue of $3.14 billion during the quarter, compared to the consensus estimate of $3.05 billion. Yum China had a return on equity of 15.82% and a net margin of 7.84%.The business’s quarterly revenue was up 12.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.58 earnings per share. On average, analysts anticipate that Yum China will post 2.95 EPS for the current fiscal year. Yum China Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Thursday, September 17th. Stockholders of record on Thursday, August 27th will be paid a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Thursday, August 27th. Yum China’s dividend payout ratio (DPR) is presently 42.49%.
Insiders Place Their Bets In other news, insider Duoduo (Howard) Huang sold 24,096 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $47.08, for a total value of $1,134,439.68. Following the sale, the insider directly owned 7,589 shares of the company’s stock, valued at approximately $357,290.12. This represents a 76.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jeff Kuai sold 14,586 shares of the stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $47.72, for a total value of $696,043.92. Following the sale, the insider owned 63,541 shares of the company’s stock, valued at approximately $3,032,176.52. The trade was a 18.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.44% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth YUMC has been the topic of several research analyst reports. The Goldman Sachs Group reissued a “buy” rating and issued a $59.00 price target on shares of Yum China in a report on Thursday, July 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Yum China in a report on Friday, August 21st. Finally, Wall Street Zen upgraded shares of Yum China from a “hold” rating to a “buy” rating in a research note on Monday, August 17th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Yum China presently has an average rating of “Moderate Buy” and a consensus price target of $59.21.
Read Our Latest Analysis on Yum China
Yum China Profile (Free Report)
Yum China Holdings, Inc operates as the largest quick-service restaurant company in China, through its ownership and franchising of brands such as KFC, Pizza Hut and Taco Bell. The company’s core business encompasses full-service and fast‐casual dining, takeout and delivery channels, as well as ancillary services including loyalty programs and digital ordering platforms. Yum China’s restaurants offer a diverse menu that adapts global brand concepts to local consumer preferences, featuring items such as soy‐marinated chicken, customized pizzas and region‐inspired side dishes.
In addition to its signature brands, Yum China has expanded its portfolio to include innovative concepts tailored to evolving market trends, such as plant‐based offerings, self‐service kiosks and mobile app integrations.
Further Reading Five stocks we like better than Yum China The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now Dropping the Dough: Yum! Brands Strategically Trims the Fat These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Yum China Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yum China and related companies with MarketBeat.com's FREE daily email newsletter.
B. Metzler seel. Sohn & Co. AG ve 2. čtvrtletí zvýšila podíl v UMB Financial o 14,7 % na 43 882 akcií. Banka zároveň oznámila čtvrtletní dividendu 0,50 USD na akcii, dříve 0,43 USD.
B. Metzler seel. Sohn & Co. AG increased its stake in shares of UMB Financial Corporation (NASDAQ:UMBF – Free Report) by 14.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,882 shares of the bank’s stock after buying an additional 5,621 shares during the period. B. Metzler seel. Sohn & Co. AG owned 0.06% of UMB Financial worth $6,265,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the stock. Greenleaf Trust increased its stake in shares of UMB Financial by 4.7% in the 2nd quarter. Greenleaf Trust now owns 2,506 shares of the bank’s stock valued at $358,000 after buying an additional 113 shares during the period. United Capital Financial Advisors LLC acquired a new position in shares of UMB Financial during the second quarter valued at $347,000. Equitable Holdings Inc. acquired a new position in shares of UMB Financial during the second quarter valued at $234,000. Public Employees Retirement System of Ohio bought a new position in UMB Financial in the second quarter valued at about $6,071,000. Finally, Capstone Investment Advisors LLC bought a new position in UMB Financial in the second quarter valued at about $415,000. Institutional investors own 87.78% of the company’s stock.
Analyst Ratings Changes Several analysts have commented on UMBF shares. Piper Sandler reiterated an “overweight” rating and set a $181.00 target price (up from $161.00) on shares of UMB Financial in a research report on Thursday, July 30th. Keefe, Bruyette & Woods raised their price target on UMB Financial from $155.00 to $160.00 and gave the stock an “outperform” rating in a research report on Thursday, July 30th. Barclays reaffirmed an “overweight” rating and set a $175.00 price objective (up from $170.00) on shares of UMB Financial in a research note on Monday, August 3rd. TD Cowen reiterated a “buy” rating and issued a $166.00 price objective (up from $161.00) on shares of UMB Financial in a report on Thursday, July 30th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of UMB Financial in a research note on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, UMB Financial presently has a consensus rating of “Moderate Buy” and an average target price of $166.54.
Read Our Latest Research Report on UMBF UMB Financial Stock Performance UMBF opened at $143.44 on Friday. The business’s 50-day moving average price is $144.93 and its two-hundred day moving average price is $131.13. UMB Financial Corporation has a 1 year low of $68.92 and a 1 year high of $144.21. The company has a market capitalization of $10.89 billion, a price-to-earnings ratio of 11.94, a P/E/G ratio of 0.69 and a beta of 0.77. The company has a debt-to-equity ratio of 0.06, a current ratio of 0.76 and a quick ratio of 0.76.
UMB Financial (NASDAQ:UMBF – Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The bank reported $3.57 EPS for the quarter, topping analysts’ consensus estimates of $3.12 by $0.45. The business had revenue of $778.00 million for the quarter, compared to analyst estimates of $727.63 million. UMB Financial had a net margin of 21.64% and a return on equity of 13.41%. During the same quarter in the previous year, the firm posted $2.96 earnings per share. Equities analysts expect that UMB Financial Corporation will post 13.5 EPS for the current fiscal year.
UMB Financial Increases Dividend The company also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Thursday, September 10th will be paid a $0.50 dividend. This is an increase from UMB Financial’s previous quarterly dividend of $0.43. The ex-dividend date is Thursday, September 10th. This represents a $2.00 annualized dividend and a yield of 1.4%. UMB Financial’s dividend payout ratio (DPR) is 14.32%.
Insider Buying and Selling at UMB Financial In related news, President James D. Rine sold 8,246 shares of the business’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $132.59, for a total transaction of $1,093,337.14. Following the transaction, the president directly owned 61,446 shares of the company’s stock, valued at approximately $8,147,125.14. The trade was a 11.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO J. Kemper sold 15,062 shares of the stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $148.55, for a total value of $2,237,460.10. Following the completion of the sale, the chief executive officer owned 1,491,138 shares in the company, valued at approximately $221,508,549.90. This trade represents a 1.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 34,171 shares of company stock valued at $4,919,826 in the last three months. Corporate insiders own 5.33% of the company’s stock.
UMB Financial Company Profile (Free Report)
UMB Financial Corporation (NASDAQ: UMBF) is a diversified financial services holding company headquartered in Kansas City, Missouri. Through its principal banking subsidiary, UMB Bank, N.A., the company provides a full suite of commercial and consumer banking services. Key offerings include deposit accounts, commercial and consumer lending, treasury and cash management, as well as online and mobile banking solutions designed to serve businesses, individuals and municipalities.
In addition to its core banking operations, UMB Financial delivers wealth management and trust services, investment advisory, asset management and retirement planning to high-net-worth individuals, families and institutions.
Featured Stories Five stocks we like better than UMB Financial The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now Dropping the Dough: Yum! Brands Strategically Trims the Fat These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern Want to see what other hedge funds are holding UMBF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UMB Financial Corporation (NASDAQ:UMBF – Free Report).
Receive News & Ratings for UMB Financial Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UMB Financial and related companies with MarketBeat.com's FREE daily email newsletter.
BlackRock Inc. purchased a new stake in shares of Hercules Capital, Inc. (NYSE:HTGC – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 924,105 shares of the financial services provider’s stock, valued at approximately $14,573,000. BlackRock Inc. owned approximately 0.49% of Hercules Capital at the end of the most recent reporting period.
Several other hedge funds have also modified their holdings of HTGC. Fox Run Management L.L.C. increased its position in Hercules Capital by 2.8% in the fourth quarter. Fox Run Management L.L.C. now owns 24,354 shares of the financial services provider’s stock worth $458,000 after purchasing an additional 657 shares during the last quarter. Centaurus Financial Inc. raised its position in shares of Hercules Capital by 1.8% during the 3rd quarter. Centaurus Financial Inc. now owns 37,819 shares of the financial services provider’s stock valued at $715,000 after buying an additional 675 shares in the last quarter. Mariner LLC raised its position in shares of Hercules Capital by 1.4% during the 4th quarter. Mariner LLC now owns 56,453 shares of the financial services provider’s stock valued at $1,062,000 after buying an additional 764 shares in the last quarter. Baker Avenue Asset Management LP lifted its holdings in shares of Hercules Capital by 8.0% in the 4th quarter. Baker Avenue Asset Management LP now owns 11,896 shares of the financial services provider’s stock valued at $224,000 after acquiring an additional 881 shares during the last quarter. Finally, Integrated Wealth Concepts LLC grew its position in Hercules Capital by 5.9% in the first quarter. Integrated Wealth Concepts LLC now owns 17,241 shares of the financial services provider’s stock worth $331,000 after acquiring an additional 959 shares in the last quarter. 19.69% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In A number of brokerages have issued reports on HTGC. Weiss Ratings restated a “hold (c)” rating on shares of Hercules Capital in a research report on Wednesday, June 17th. UBS Group upgraded Hercules Capital from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $15.50 to $18.50 in a report on Tuesday. Finally, LADENBURG THALM/SH SH decreased their price target on Hercules Capital from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Hercules Capital presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.89.
Get Our Latest Stock Report on Hercules Capital Hercules Capital Trading Up 0.1% HTGC opened at $17.72 on Friday. The stock’s fifty day moving average is $16.54 and its two-hundred day moving average is $15.69. The company has a market capitalization of $3.32 billion, a P/E ratio of 8.82 and a beta of 0.81. Hercules Capital, Inc. has a 52 week low of $13.70 and a 52 week high of $19.62. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.03.
Hercules Capital (NYSE:HTGC – Get Free Report) last issued its earnings results on Thursday, July 30th. The financial services provider reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.02. The business had revenue of $134.41 million during the quarter, compared to analysts’ expectations of $146.71 million. Hercules Capital had a return on equity of 16.01% and a net margin of 67.68%.The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.50 EPS. Analysts forecast that Hercules Capital, Inc. will post 1.95 earnings per share for the current year.
Hercules Capital Increases Dividend The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 18th. Shareholders of record on Tuesday, August 11th were given a dividend of $0.40 per share. This is a positive change from Hercules Capital’s previous quarterly dividend of $0.07. The ex-dividend date of this dividend was Tuesday, August 11th. This represents a $1.60 dividend on an annualized basis and a yield of 9.0%. Hercules Capital’s payout ratio is 79.60%.
Hercules Capital Profile (Free Report)
Hercules Capital, Inc is a specialty finance company organized as a business development company (BDC) that provides tailored debt financing solutions to high‐growth companies. Through its external management structure, Hercules Capital extends senior secured loans, subordinated debt and growth capital designed to support research and development, expansion initiatives and working capital needs. The firm primarily partners with venture capital and private equity sponsors to finance innovative enterprises across various developmental stages.
The company’s investment portfolio is concentrated in technology, life sciences and sustainable and renewable technology sectors, reflecting its focus on industries with strong growth prospects and recurring capital requirements.
Read More Five stocks we like better than Hercules Capital The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now Dropping the Dough: Yum! Brands Strategically Trims the Fat These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Hercules Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hercules Capital and related companies with MarketBeat.com's FREE daily email newsletter.
Baypointe Partners LLC bought a new stake in shares of Ulta Beauty Inc. (NASDAQ:ULTA – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 15,000 shares of the specialty retailer’s stock, valued at approximately $6,765,000. Ulta Beauty makes up about 16.2% of Baypointe Partners LLC’s holdings, making the stock its 2nd biggest holding.
Several other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Ulta Beauty during the 2nd quarter valued at $1,815,712,000. State Street Corp grew its holdings in shares of Ulta Beauty by 2.5% during the 4th quarter. State Street Corp now owns 2,025,565 shares of the specialty retailer’s stock worth $1,225,487,000 after acquiring an additional 50,305 shares during the period. Diamant Asset Management Inc. boosted its holdings in shares of Ulta Beauty by 52,171.0% during the 1st quarter. Diamant Asset Management Inc. now owns 1,474,042 shares of the specialty retailer’s stock valued at $77,050,000 after buying an additional 1,471,222 shares in the last quarter. Geode Capital Management LLC grew its holdings in Ulta Beauty by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 1,240,210 shares of the specialty retailer’s stock worth $747,587,000 after purchasing an additional 21,947 shares during the period. Finally, T. Rowe Price Investment Management Inc. grew its stake in shares of Ulta Beauty by 0.3% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 974,223 shares of the specialty retailer’s stock worth $589,415,000 after buying an additional 2,463 shares during the last quarter. Institutional investors own 90.39% of the company’s stock.
Ulta Beauty Stock Up 1.0% ULTA stock opened at $557.11 on Friday. The firm has a market capitalization of $23.82 billion, a P/E ratio of 20.30, a price-to-earnings-growth ratio of 1.65 and a beta of 0.85. Ulta Beauty Inc. has a 52 week low of $443.60 and a 52 week high of $714.97. The company has a fifty day simple moving average of $503.61 and a two-hundred day simple moving average of $529.93.
Ulta Beauty (NASDAQ:ULTA – Get Free Report) last issued its quarterly earnings data on Thursday, August 27th. The specialty retailer reported $6.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.22 by $0.33. The business had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.99 billion. Ulta Beauty had a return on equity of 45.40% and a net margin of 9.34%.The company’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the business posted $5.78 earnings per share. Ulta Beauty has set its FY 2026 guidance at 28.700-29.000 EPS. As a group, analysts anticipate that Ulta Beauty Inc. will post 28.93 EPS for the current year. Wall Street Analysts Forecast Growth A number of research firms have weighed in on ULTA. JPMorgan Chase & Co. reduced their price objective on shares of Ulta Beauty from $750.00 to $631.00 and set an “overweight” rating for the company in a research note on Wednesday, June 3rd. Raymond James Financial reissued a “strong-buy” rating and issued a $700.00 target price on shares of Ulta Beauty in a report on Friday, August 28th. Argus set a $550.00 price objective on shares of Ulta Beauty in a research report on Thursday, June 18th. Morgan Stanley cut their price objective on Ulta Beauty from $700.00 to $630.00 and set an “overweight” rating for the company in a research note on Wednesday, June 3rd. Finally, Barclays cut their price target on Ulta Beauty from $647.00 to $645.00 and set an “overweight” rating for the company in a research note on Friday, August 28th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $626.59.
Check Out Our Latest Stock Report on Ulta Beauty
Key Stories Impacting Ulta Beauty Here are the key news stories impacting Ulta Beauty this week:
Positive Sentiment: Analyst upgrade supports the shares. Ulta Beauty gained attention after an analyst upgrade, adding to recent positive momentum and reinforcing confidence in the retailer’s earnings outlook. Ulta Beauty Trading Up After Analyst Upgrade Positive Sentiment: Recent earnings and guidance remain key catalysts. Ulta reported quarterly revenue of approximately $3.04 billion and adjusted earnings of $6.55 per share, exceeding consensus estimates. Sales increased 8.9% year over year, while the company raised fiscal 2026 earnings guidance to roughly $28.70–$29.00 per share. Continued growth in prestige hair care also supports the investment case. Ulta Beauty Earnings Beat Keeps Valuation In Focus Positive Sentiment: Loss-prevention efforts could help margins. Ulta is using Flock license-plate cameras at some stores, a move that may deter organized retail crime and reduce merchandise losses, although privacy and implementation considerations remain. Ulta Beauty Is Using Flock Cameras at Some Stores Neutral Sentiment: Investor conference participation may provide additional outlook commentary. Management’s upcoming conference appearance could offer updates on consumer demand, store growth and guidance, but no new financial information was announced. Ulta Beauty to Participate in Upcoming Investor Conference Neutral Sentiment: Promotional activity is intensifying. Ulta’s 21+ Days of Beauty and Labor Day promotions may drive traffic and sales, but heavier discounting could pressure margins. Ulta 21+ Days of Beauty Event Negative Sentiment: Valuation and slowing comps remain risks. Analysts noted that the earnings beat was accompanied by moderating comparable-sales growth, while valuation screens suggest the stock may already reflect much of the improved guidance. Ulta Beauty’s Earnings Beat Was Stronger Than the Stock’s Reaction Ulta Beauty Stock Could Be Overvalued Negative Sentiment: Shoplifting and competition remain headwinds. A reported shoplifting incident highlights ongoing shrink risk, while Target’s planned beauty studios could increase competitive pressure in beauty retail. Lexington Police Work to Identify Alleged Ulta Beauty Shoplifter Target Beauty Studios Debuting Insiders Place Their Bets In other Ulta Beauty news, Director George R. Mrkonic, Jr. sold 383 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $475.84, for a total value of $182,246.72. Following the completion of the sale, the director owned 2,404 shares of the company’s stock, valued at $1,143,919.36. This trade represents a 13.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.20% of the stock is owned by company insiders.
Ulta Beauty Company Profile (Free Report)
Ulta Beauty, Inc (NASDAQ: ULTA) is a U.S.-based specialty retailer and beauty services provider focused on cosmetics, fragrance, skin care, hair care, bath and body, and beauty tools. The company operates a dual-format business that combines brick-and-mortar retail stores with an e-commerce platform, offering a broad assortment of national, prestige and mass-market brands alongside its own private-label products. In many locations Ulta also provides full-service salon treatments, positioning the company as a one-stop destination for product discovery and in-store services.
The retailer’s product mix spans color cosmetics, haircare and styling products, skin and body care, fragrance, and accessories, catering to a wide range of consumer preferences and price points.
See Also Five stocks we like better than Ulta Beauty The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now Dropping the Dough: Yum! Brands Strategically Trims the Fat These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Ulta Beauty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ulta Beauty and related companies with MarketBeat.com's FREE daily email newsletter.
Lululemon podruhé snížil celoroční výhled, což poslalo akcie v premarketu dolů asi o 18 %. Firma zároveň čelí tlaku na marže, slabší poptávce a ztrátě podílu na trhu.
Shares of Lululemon Athletica (LULU.O) fell about 18% in premarket trading on Friday after the sportswear maker cut its full-year forecast for a second time, underscoring the string of challenges that await incoming CEO Heidi O'Neill.
Known for its high-priced stretchy pants and athletic tops, Lululemon has struggled to contain shrinking margins, worsening brand perception and market-share loss to new rivals. O'Neill, who takes over on September 8, will have to chart a recovery for a company hit by merchandising missteps, an over-reliance on promotions and intensifying competition.
The firm's shares were trading at about $99 before the bell, and if losses hold, Lululemon would lose more than $2.5 billion in market value, deepening the stock's year-to-date decline to about 41.5%.
"In our view, last night's decidedly downbeat quarterly announcement is now apt to unnerve meaningfully even longer-term-oriented investors examining the name," said Brian Nagel, analyst at Oppenheimer Research, in a note.
Investors should await an initial game plan from O'Neill before considering a more constructive stance on shares, he added.
O'Neill, a former Nike executive, will be tasked with reviving demand in North America, Lululemon's largest market, and restoring growth.
Revenue in the Americas fell 8% from a year earlier in the second quarter, compared with a 1% increase the previous year, as the firm struggled to reignite demand amid slow consumer spending impacted by inflationary pressures.
Sales could deteriorate further in the second half, Morgan Stanley said, with limited visibility on when demand might recover, raising the risk of continued pressure on margins.
Following the results, at least 12 brokerages lowered their price objectives for the shares, with Piper Sandler setting the Street-low target of $80, according to data compiled by LSEG.
Lululemon's shares trade at about 11.50 times forward earnings, compared with 20.76 for peers Nike (NKE.N) and 13.41 for Adidas (ADSGn.DE).
Akcie Premier African Minerals klesly o více než 27 % poté, co společnost oznámila plán vydat až 58,63 miliardy nových akcií kvůli financování projektu Zulu a posílení bilance. Akcionáři budou hlasovat 23. září.
Premier African Minerals Ltd (AIM:PREM, OTC:PRMMF) shares dropped more than 27% to 0.1p on Friday after the company outlined plans to seek authority to issue tens of billions of new shares as it looks to fund the Zulu lithium project and strengthen its balance sheet.
Premier called a general meeting for 23 September, where shareholders will vote on proposals including authority to issue up to 58.63 billion ordinary shares to support the operational and funding plan for its Zulu Lithium and Tantalum Project in Zimbabwe.
A further 5.40 billion shares could be issued to settle outstanding creditor obligations, including approximately US$880,000 owed to J R Goddard Contracting and US$289,064 owed to China Zenith Capital.
Another resolution would authorise up to 8.57 billion shares for Canmax Technologies under existing conversion rights.
Premier's current financial forecast identifies a funding requirement of around $19.1 million through to the end of 2027, with the proposed initial share authority providing capacity to raise approximately $12.7 million based on a 0.016p share price.
Shareholders will also be asked to approve a further 10-for-one share consolidation, aimed at reducing the company's more than 50 billion shares currently in issue.
Premier cautioned that it has limited funds and needs additional financing to meet its obligations, warning that failure to secure funding could materially affect both Zulu and the group's financial position.
Joby Aviation kupuje Resonant Sciences za přibližně 500 milionů USD, přičemž hotovostní část činí 450 milionů USD a 50 milionů USD v akciích. Akvizice má téměř zdvojnásobit jeho výnosy.
Shares of Joby Aviation (JOBY +0.73%) trade below $7 as of this writing, near their 52-week low, having lost about two-thirds of their value from a 52-week high of nearly $20. Investors, it seems, may be tired of waiting for electric air taxis to turn into meaningful revenue.
The company, meanwhile, isn't waiting. On Aug. 11, Joby announced an agreement to acquire Resonant Sciences, a defense technology company, for about $500 million -- about $450 million in cash plus $50 million in stock. It's a purchase big enough to roughly double Joby's revenue base.
Half a billion dollars is serious money for a company that still spends far more than it takes in. Here's a closer look at what the deal costs -- and what shareholders get.
Image source: Joby Aviation.
Fast growth in defenseResonant, based in Dayton, Ohio, builds radio frequency (RF) and mission systems for U.S. national security customers. It also specializes in low-observability technology. In simpler terms, its systems help military aircraft sense their surroundings and avoid detection.
Not only did Resonant generate more than $100 million of revenue over its trailing twelve months, up about 40% year over year, but the business also produces positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA). And demand is accelerating. In the first half of 2026, Resonant booked more than three times as much new business as it did a year earlier, and its backlog more than doubled year over year.
Joby's own outlook, raised in August, calls for full-year 2026 revenue of $115 million to $125 million. Resonant's trailing-twelve-month revenue, in other words, is nearly as large as everything Joby expects to book this year.
However, the deal isn't expected to close until the first half of 2027, subject to regulatory reviews. None of Resonant's results are in Joby's numbers yet.
Can Joby afford it?Joby can afford the deal, I think, at least on today's balance sheet.
Joby's cash and short-term investments stood at about $2.3 billion at the end of June. Management expects to use between $385 million and $415 million of it in the second half of 2026 alone. The $450 million going to Resonant works out to about a fifth of the war chest.
In February, Joby raised about $576 million in net proceeds from a stock offering and another $670 million from an offering of convertible notes. The company, in other words, is spending cash investors handed it months ago, not cash the business generated.
Between the guided second-half cash use and the Resonant payment, about $850 million of the June 30 balance is already spoken for. The $50 million of stock barely registers, adding less than 1% to the share count. However, on the same day it announced the deal, Joby also put a program in place to sell up to $750 million in new stock over time.
Joby stock is still an air taxi betAlmost none of Joby's revenue today comes from electric air taxis.
Of the $38.6 million the company reported for the second quarter, $36.2 million came from passenger flights booked through Blade (the passenger business Joby acquired in August 2025). Blade's demand peaks in the summer, and the second quarter's $38.6 million was up from about $24 million in the first. And the full-year outlook implies a second half no bigger than the first, not an acceleration.
But the air taxi business itself isn't generating revenue yet. Joby said in its August update that it made its strongest quarterly progress yet in the fifth and final stage of FAA type certification. The company is still targeting its first passenger flights before the end of 2026, with the first flights under a federal pilot program expected in Texas this month.
The price of the deal also looks reasonable next to Joby's own valuation. At a market capitalization of about $6.7 billion, Joby trades at more than 50 times the midpoint of its 2026 revenue outlook. Resonant, by comparison, is being bought for less than 5 times its trailing sales -- a modest price, I'd argue, for a business growing about 40%.
Premium Feature
Moneyball Superscore
66/100
Today's Change
(
0.73
%) $
0.05
Current Price
$
6.87
Investors, in short, aren't paying for the revenue Joby has today. They're paying for the air taxi business it hopes to build.
Ultimately, the acquisition strikes me as a sensible use of Joby's cash. It buys a business that could keep growing whether or not air taxis arrive on schedule. But the deal doesn't change what this growth stock is: a bet that electric air taxis become a big business before the cash runs low.
Of course, the certification work isn't finished, and the first paying passengers haven't flown. I would avoid buying shares here. If those passengers arrive on schedule and spending starts to fall, I would consider changing my mind.
Arrow Exploration oznámila rekordní produkci přes 6 000 boe/d. IC-6 narazila na poruchu a byla dokončena jako vodní injektor, což má snížit provozní náklady.
Calgary, Alberta--(Newsfile Corp. - September 4, 2026) - Arrow Exploration Corp. (AIM: AXL) (TSXV: AXL) ("Arrow" or the "Company"), the high-growth operator with a portfolio of assets across key Colombian and Canadian hydrocarbon basins, is pleased to provide an update on operational activity at the Icaco field on the Tapir Block in the Llanos Basin of Colombia where Arrow holds a 50 percent beneficial interest.
Production
Current total corporate production is over 6,000 boe/d, including production from the recently acquired Thorsby field in Alberta, Canada. This is a record high production rate for the Company and reflects recent drilling successes, outstanding results from workovers and the Thorsby acquisition. Arrow believes it can continue to grow production from its prospect-rich inventory.
Cash Balance
As of September 1, 2026, after the Thorsby acquisition payment of US$8.9m, the Company's estimated cash balance is US$21.8 million. The Company continues to enjoy a strong balance sheet while growing production and associated cash balance.
Icaco-6 Well
The Icaco 6 well (IC-6) was spud on 19th August 2026 and reached a total depth on 24th August 2026. The IC-6 well encountered a fault and experienced lost circulation and associated drilling mud losses before reaching the target depth. Management, out of an abundance of caution, made the decision to case the well prematurely and complete it as a much-needed, water disposal well. The additional water disposal capacity will have a very positive impact on reducing operating costs.
Log analysis in the IC-6 well shows that the well encountered 6.5 feet MD (4 feet TVD) of net pay in the Carbonera C7 formation ("C7") and 5 feet MD (3 feet TVD) of net pay in the Guadalupe Formation with Management encouraged with reservoir quality. The well was terminated before it reached the Gacheta and Ubaque formations.
Forward Drilling Plans
The IC-7 well was spud on 1st September and will be a vertical well with C7, Gacheta and Ubaque targets.
Tapir Extension
Arrow continues constructive discussions with regulatory bodies on the Tapir extension. The recent Presidential election resulted in a forward looking Government that is pro-business. In line with President De La Espriella's vision to increase Colombia's oil and gas development, Arrow is looking forward to being a part of the President's vision.
Marshall Abbott, CEO of Arrow commented:
"Arrow is very proud to surpass the 6,000 boe/d threshold. The additional production from drilling and workovers highlights the continued operational success the Company has had on the Tapir block. The multi-zone quality of the Icaco discovery, and its commensurate production rates, have surpassed initial expectations.
"Arrow is building another five cellars on the Icaco pad, bringing the total number to fifteen, to continue drilling C7, Gacheta and Ubaque wells.
"Although the IC-6 well was terminated sooner than expected due to encountering a fault, we were able to quickly pivot and complete the well as a water injector in a cost effective manner which will significantly help water handling and production efficiency at Icaco. Meanwhile, the best production wells in the Icaco block have paid out in less than 2 months and production continues to be strong from these wells.
"The Company continues to experience strong netbacks. This adds significant value and materially strengthens our balance sheet. We look forward to updating our shareholders on further progress at Icaco over the coming months."
Arrow Exploration Corp. (operating in Colombia via a branch of its 100% owned subsidiary Carrao Energy S.A.) is a publicly traded company with a portfolio of premier Colombian oil assets that are underexploited, under-explored and offer high potential growth. The Company's business plan is to expand oil production from some of Colombia's most active basins, including the Llanos, Middle Magdalena Valley (MMV) and Putumayo Basin. The asset base is predominantly operated with high working interests, and the Brent-linked light oil pricing exposure combines with low royalties to yield attractive potential operating margins. By way of a private commercial contract with the recognized interest holder before Ecopetrol S.A., Arrow is entitled to receive 50% of the production from the Tapir block. The formal assignment to the Company is subject to Ecopetrol's consent. Arrow's seasoned team is led by a hands-on executive team supported by an experienced board. Arrow is listed on the AIM market of the London Stock Exchange and on TSX Venture Exchange under the symbol "AXL".
Forward-looking Statements
This news release contains certain statements or disclosures relating to Arrow that are based on the expectations of its management as well as assumptions made by and information currently available to Arrow which may constitute forward-looking statements or information ("forward-looking statements") under applicable securities laws. All such statements and disclosures, other than those of historical fact, which address activities, events, outcomes, results or developments that Arrow anticipates or expects may, could or will occur in the future (in whole or in part) should be considered forward-looking statements. In some cases, forward-looking statements can be identified by the use of the words "continue", "expect", "opportunity", "plan", "potential" and "will" and similar expressions. The forward-looking statements contained in this news release reflect several material factors and expectations and assumptions of Arrow, including without limitation, Arrow's evaluation of the impacts of COVID-19, the potential of Arrow's Colombian and/or Canadian assets (or any of them individually), the prices of oil and/or natural gas, and Arrow's business plan to expand oil and gas production and achieve attractive potential operating margins. Arrow believes the expectations and assumptions reflected in the forward-looking statements are reasonable at this time, but no assurance can be given that these factors, expectations, and assumptions will prove to be correct.
The forward-looking statements included in this news release are not guarantees of future performance and should not be unduly relied upon. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company undertakes no obligations to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Qualified Person's Statement
The technical information contained in this announcement has been reviewed and approved by Grant Carnie, senior non-executive director of Arrow Exploration Corp. Mr. Carnie was formerly a member of the Canadian Society of Petroleum Geologists, holds a B.Sc. in Geology from the University of Alberta and has over 35 years' experience in the oil and gas industry.
This Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").
Glossary
Pay A reservoir or portion of a reservoir that contains economically producible hydrocarbons NOT FOR RELEASE, DISTRIBUTION, PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312905
Source: Arrow Exploration Corp.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
SpaceX uvedla 12,0 milionu předplatitelů Starlinku, což je oproti 1. čtvrtletí nárůst o 16,5 %. Měsíční ARPU zůstal na 66 USD, i když firma přidala 1,7 milionu nových zákazníků.
When recently IPO'd Space Exploration Technologies (SPCX +6.42%), or SpaceX, released its first quarterly earnings report, there wasn't much in it that was unexpected.
Revenue grew. Net loss shrank. Capital expenditures in the AI business skyrocketed. Ho hum. But buried in the report were a pair of numbers that made me do a double-take. I had to check to make sure I read them correctly.
These two numbers could actually be a game changer for SpaceX's profitability. Here's what they are and why they're important.
Image source: Getty Images.
Buried on page 5 SpaceX highlighted its biggest, boldest numbers on page 1 of its report, boasting about its $14.1 billion in contracted Cloud Services Agreements sales, and its $6 billion in multi-year government Starshield contracts.
But on page 5 -- literally halfway through the 10-page report -- these two numbers caught my eye: 12.0 and $66.
12.0 is the number of subscribers, in millions, for SpaceX's Starlink satellite broadband and wireless network, which offers communications access to people around the globe who aren't served by traditional cellular towers or internet cable networks.
That's actually a sizable 16.5% jump from the 10.3 million Starlink subscribers that SpaceX reported in the first quarter, and it's double the 6 million Starlink subscribers that SpaceX reported in the second quarter of 2025.
The other number -- $66 -- is where it really gets interesting.
Image source: The Motley Fool.
Holding steady $66 is the monthly average revenue per user (ARPU) of those 12 million Starlink subscribers. That's unchanged from Q1 ... which is a big surprise.
In Q2 2025, Starlink's monthly ARPU was $85 for its 6 million subscribers. When that shrank to $66 for 10.3 million subscribers in Q1, most analysts assumed that Starlink's ARPU would continue steadily shrinking as it expanded into less profitable markets, likely at a similar rate. Instead, Starlink was able to add 1.7 million net new subscribers without margin shrinkage. That's huge.
Starlink is currently SpaceX's only profitable segment, and it's essentially offsetting all the losses from the rocket launch segment and some of the losses from the AI segment. However, if Starlink can continue to grow its subscriber base while mostly maintaining its current ARPU, the company could become profitable much earlier than most analysts -- including me -- anticipated.
Today's Change
(
6.42
%) $
9.03
Current Price
$
149.74
That said, one quarter doesn't make a trend. It's always a good idea to wait for multiple quarterly reports before buying shares of a recent IPO.
It's possible this quarter is just a blip, and Starlink's ARPU will continue to shrink in the third quarter. Or SpaceX's AI losses might accelerate faster than anticipated. With just one official quarterly report to go on, there's no way to tell.
But if this trend continues in Q3, I might have to rethink my conclusion that SpaceX is wildly overvalued.
Citigroup může získat licenci pro svou stoprocentně vlastněnou čínskou brokerskou jednotku už tento měsíc. Po spuštění chce během několika měsíců nabrat několik desítek lidí.
Citigroup (C.N) expects to get regulatory approval for its wholly-owned China brokerage business as soon as this month and plans to add several dozen staff at the unit over the next few months, said two people with knowledge of the matter.
The long-awaited final Chinese regulatory approval for the business could be granted around the time of Chinese President Xi Jinping's planned visit to Washington to meet with U.S. President Donald Trump in late September, the sources said.
The expected regulatory approval for the business as soon as this month has not been reported previously.
Citi declined to comment.
The U.S. bank, which offers corporate, institutional and other banking services in China, applied for a wholly-owned mainland Chinese brokerage unit licence in late 2021 as part of its push to ramp up its presence in the world's second-largest economy.
Citi, which has been hiring for the business over the last couple of years in preparation for the licence, aims to roughly double the headcount to around 100 people by the end of this year, said the first source.
The China expansion would see Citi competing with already licensed Wall Street rivals including JPMorgan (JPM.N), Goldman Sachs (GS.N) and Morgan Stanley (MS.N) for a share of growing and increasingly profitable onshore securities trading and underwriting deals.
The expected launch of Citi's brokerage business comes at a time when China is seeing a growing list of technology and other companies tapping domestic equity markets for fundraising and attracting increased fund flows into the stock markets.
Despite intense Sino-U.S. geopolitical tensions in recent years, Beijing has been expanding Wall Street firms' access to its financial sector worth trillions of dollars as it looks to attract more capital inflows.
The New York-headquartered bank's China hiring push will see it adding people from senior front-office bankers to support staff and will be done via a combination of internal transfers and external hires, the sources said.
They declined to be named as the expansion plans are not public.
For the China brokerage unit, Citi plans to relocate some of its bankers from Hong Kong and other markets in Asia, as well as moving some of its existing mainland staff to the new business, the first source added.
COMPETITIVE MARKET
In 2025, profits at the wholly-owned China securities unit of Goldman Sachs nearly tripled to 1.46 billion yuan ($217.39 million), while JPMorgan's almost quadrupled to 984 million yuan, as per their latest China annual reports.
Morgan Stanley's profit soared sevenfold to 138 million yuan last year, its annual report showed, as the U.S. banks benefit from surging securities trading revenue primarily from institutional clients.
Citi's new China business unit is seeking a regulatory nod to conduct A-share brokerage, underwriting, research and principal trading businesses in the onshore market, according to the sources.
Those offerings would complement the bank's existing offshore-focused China investment banking team that supports domestic companies' financing activities in overseas markets, the first source added.
The bank plans to lean on its sizeable onshore corporate and commercial banking client base, which it already serves in areas such as foreign exchange, cash management and trade finance, to win A-share equity and M&A mandates, the people said.
For the new unit, Citi will focus on sectors including technology, healthcare, consumer and financial institutions, targeting China's established corporate "champions" as well as emerging players including AI and chip companies.
Citi this week announced a 25% headcount increase across South Africa, Europe and Asia to serve its North Asian clients' outbound banking needs, including those from mainland China.
In addition to the Wall Street rivals, Citi would be competing with the dominant Chinese brokerages for its planned offering. Some foreign financial firms have exited the country in the recent past due to the hyper-competitive business environment.
Reuters reported last month that asset manager Fidelity International was planning to wind down a China fund management unit, which followed Schroders' decision to transfer its onshore team and products to peer Neuberger Berman.
The planned China expansion comes against the backdrop of Citi CEO Jane Fraser, who was the sole female global banking chief accompanying Trump on his May visit to Beijing, pushing for stronger profitability targets for the next two years.
Nvidia zvýšila své kapitálové investice za rok více než desetinásobně na 99 miliard USD a dál je využívá k podpoře ekosystému AI. Firma letos přislíbila více než 40 miliard USD.
Nvidia has become one of the world's largest strategic tech backers as the value of its equity investments soared more than tenfold in the past year to $99 billion, with the chip giant increasingly looking to leverage its huge capital reserves to bolster the AI sector.
The company has ramped up dealmaking for financing rounds across the AI stack in the previous 12 months, with over $40 billion committed in 2026. Equity investments were valued at $99 billion as of July 26, up from about $7 billion a year earlier and about $2.2 billion two years earlier.
The rise in value puts Nvidia among the strategic investors with the largest tech holdings around the world. The company still trails some more established tech firms, with Alphabet and Amazon both posting equity investments worth over $100 billion in recent earnings.
Capital has increasingly become a key play for Nvidia.
In August, the company announced partnerships with major investment firms aimed at mobilizing more than $500 billion worth of financing for Nvidia's graphics processing units (GPUs) and said it would provide up to $105 billion of conditional credit support for an OpenAI data center in Ohio. Nvidia also announced Thursday it is planning to acquire AI startup Hugging Face for $12.9 billion.
Frontier labs, neoclouds and companies building software and novel tech for AI — both in private and public markets — have been recipients of cash, with the value of Nvidia's equity holdings also buoyed by skyrocketing tech stocks.
Nvidia made the investments to enhance its growth opportunities, cultivate its ecosystem and strengthen its competitive position, the company said in its earnings.
"Nvidia has a clear interest in ensuring that its customers and partners prosper to provide future business for Nvidia," Ian Fogg, research director at CCS Insight, told CNBC. "Equity investments help companies to innovate, but also give Nvidia a degree of control to encourage companies to take a Nvidia-related innovation path."
Securing positioningNvidia dominates the market for the most advanced chips used for AI, known as graphics processing units (GPUs). Business has boomed as a result.
The chip giant has seen its stock increase by 33% over the past 12 months, and its revenue soared 106% to $96.2 billion in its fiscal second quarter.
Nvidia stock.
"Nvidia is keen to diversify its AI business," said Fogg. "In its most recent quarter, $48.7bn of $96.2bn revenue came from the Hyperscale segment which includes the largest cloud players."
The company is taking steps including financing and equity investments to "increase the range of customers and create an AI ecosystem," he added. "Some aim to support emergent cloud providers, others help Nvidia grow new markets, like telecom for example with the $1bn Nokia equity investment."
Frontier AI labs have been major recipients of Nvidia splashing the cash. The chip giant's Chief Financial Officer Colette Kress told analysts on an earnings call that the company had invested "nearly $50 billion in the frontier AI labs."
Most recently, in February, Nvidia said it would invest $30 billion into OpenAI as part of the company's $110 billion funding round.
While frontier AI labs had "extraordinary" demand for compute, they were growing faster than balance sheets and credit profiles could support and struggled to secure AI factory infrastructure independently, Kress added. "Nvidia is needed to help power this flywheel."
Neoclouds, which buy Nvidia GPUs and then rent access to companies, such as Nebius and CoreWeave, have also courted the chip giant. January saw Nvidia invest $2 billion into CoreWeave and in March it was announced that Nebius secured a $2 billion investment.
watch now
"By injecting capital directly into AI infrastructure financiers, specialized cloud providers and foundation model labs, Nvidia provides these startups with the balance sheet strength to purchase tens of thousands of Nvidia GPUs," Naveen Chhabra, principal analyst at Forrester, told CNBC.
The company has also invested in nascent technological areas. Since March, Nvidia has committed at least $6.5 billion into companies developing photonics and optical technology — which uses light to transmit data and is considered to be a more efficient alternative to transferring data using electricity.
Lumentum, Coherent and Marvell each received $2 billion investments from the tech giant.
"Optics/networking specialists, like Coherent, receive investments to ensure their tooling, NVLink protocols and design engines remain strictly optimized for Nvidia's architecture," said Chhabra. "This creates high switching costs and protects the CUDA software moat against competing accelerators from AMD or internal custom chips from cloud providers."
Nvidia has also seen its $5 billion investment in Intel soar to a value of $30 billion, while its SpaceX holding was worth $21 billion as of June.
"As global AI chip demand runs into physical supply constraints particularly around high-bandwidth memory (HBM) and advanced packaging, Nvidia uses strategic equity positions like in domestic manufacturing options like Intel, to secure priority manufacturing access, reduce Asian foundry concentration risk and stabilize key component supplies," said Chhabra.
Peloton vykázal první roční čistý zisk přes 63 milionů USD, ale trh znepokojil téměř 9% pokles placených connected fitness předplatných na něco přes 2,55 milionu. Akcie v srpnu klesly o 16 %.
In the middle of August, Peloton (PTON +0.94%) posted its fourth-quarter and fiscal year 2026 results, which were marked by the company's first annual net profit.
Such an achievement would ordinarily be cause for celebration for many investors, but Peloton's clearly weren't in a festive mood. Instead, they traded out of the stock to leave it with a 16% decline in August. Let's explore why that happened.
Image source: Getty Images.
Stalling subscriptions Peloton, which specializes in next-generation exercise bikes and the class subscriptions that accompany them, posted those results on Aug. 6. The company hyped that full-year net profit, which was more than $63 million and far more impressive than the fiscal 2025 loss of almost $119 million. This, despite an erosion on the top line, to $2.45 billion from $2.49 billion.
The company also landed in the black in the final quarter of fiscal 2026, with the bottom line nearly tripling year over year to just under $62 million. Yet the revenue line wasn't all that impressive, with only marginal growth to nearly $608 million.
At least Peloton beat the consensus analyst top-line estimate of $597 million, and edged past the collective $0.12 per share collective analyst forecast for net income.
But market players had their eye on another important metric, and they understandably found it wanting. Paid connected fitness subscriptions were slightly over 2.55 million at the end of the fiscal year, down almost 9%.
The company's members -- i.e., customers who have a connected fitness subscription or a subscription to one of its apps, and have finished at least one workout over the past year -- also declined, to 5.5 million from 6 million.
Subscriptions are recurring and bring in far more revenue than sales of hardware like bikes. The total take for the former was $437 million in the fourth quarter, compared with nearly $171 million for the latter.
Price hikes on Peloton's monthly plans helped goose subscription revenue, as that $437 million was 7% higher year over year. But that's not a good substitute for organic member/subscription count growth, and it isn't a lever that can be pulled often without annoying customers.
Premium Feature
Moneyball Superscore
50/100
Today's Change
(
0.94
%) $
0.05
Current Price
$
5.38
A trend that needs reversing Not only did Peloton disappoint investors, but it also lost a bit of luster in the eyes of an analyst at a prominent financial institution.
Shortly after those quarterly and annual figures were released, Bank of America's Curtis Nagle shaved his Peloton price target to $7 per share from $7.50, although he maintained his buy recommendation on the stock. He cited the subscriber dynamic in his explanation of the price cut.
The great challenge for a subscription-based business is that the offering party must provide sufficient value for money to justify the recurring charges. That's proving to be tough for Peloton, and I don't envision the stock doing well if management can't reverse this trend.
Anthropic se blíží finalizaci rozšíření své revolvingové úvěrové facility na 15 miliard USD, což by mělo předcházet jeho očekávanému IPO. Na vedení transakce se podílí Morgan Stanley, Goldman Sachs, JPMorgan Chase a Citigroup.
Anthropic is close to finalising an expansion of its revolving credit facility to $15 billion, according to people familiar with the matter, clearing a key hurdle before the AI company files publicly for its highly anticipated IPO.
Morgan Stanley (NYSE:MS) is leading the process, with Goldman Sachs, JPMorgan Chase and Citigroup also holding prominent roles on the facility. The same four lenders are reported to be leading the IPO itself.
Raise seen rivalling SpaceX
The Claude chatbot maker is seeking to raise as much as SpaceX or more in its initial public offering, according to people familiar with the preparations. Companies typically finalise a revolver of this kind before formally notifying banks of their roles in a listing — making the credit facility a signal of IPO timing as much as a financing event in its own right.
Wider banking syndicate
Barclays and Wells Fargo are also expected to take key roles on the loan, with Bank of America, Deutsche Bank, Royal Bank of Canada (TSX:RY) and UBS ranked high in the facility's lineup. Bank of Montreal, BNP Paribas, Crédit Agricole, Mizuho, Mitsubishi UFJ, Sumitomo Mitsui and Toronto-Dominion Bank (TSX:TD) round out the syndicate.
In syndicated loans, a bank's fee income generally scales with its commitment — meaning a higher ranking on the facility can also point to a more active role should the IPO proceed.
Above initial target
The facility would exceed the roughly $10 billion target reported last month. Anthropic had asked the most active lead banks to commit about $1.25 billion each, with the next tier encouraged to offer around $1 billion, and commitments falling to roughly $750 million or lower for less active participants, according to the earlier reporting.
Terms still in flux
Details of the loan could still change, the people said, speaking on condition of anonymity as the information isn't public. Representatives for Anthropic, JPMorgan, Barclays, Wells Fargo and UBS declined to comment; the other banks did not immediately respond to requests for comment.
Akcie Robinhood v srpnu vzrostly o 21 % díky silným čtvrtletním výsledkům a rally kryptoměn. Tržby stouply meziročně o 32 % na více než 1,3 miliardy USD a čistý zisk o 45 % na 561 milionů USD.
Robinhood Markets (HOOD +16.57%) barreled into August just after publishing an estimates-crushing quarterly earnings report, and its stock only got more popular from there. Thanks in no small part to a rally in cryptocurrencies -- a major focus of the brokerage and financial services company -- its shares ended the month 21% higher.
Monster momentum The stage was set at the end of July for a pronounced Robinhood rally. Its second-quarter results featured a strong 32% year-over-year gain in revenue (to over $1.3 billion), while headline net profit surged 45% higher to $561 million. Both figures were well higher than the average analyst estimates.
Image source: Getty Images.
One negative note in that earnings report was the transaction-based revenue from cryptocurrencies, which sank by 38% to $100 million.
However, worries about this were erased mere weeks later as cryptocurrencies staged an impressive and sustained rally just after mid-August.
Several developments ignited this comeback, including the Treasury Department's promise to double the size of its regular long-term government bond repurchases. President Trump's push for Congress to pass the CLARITY Act, which would provide a regulatory framework for the cryptocurrency industry, also helped.
Rising crypto prices inspired more investors to pile into digital coins and tokens, and Robinhood is one of the brokerages that has embraced crypto trading most enthusiastically. So as cryptos went, so went the company's stock.
Another niche Robinhood dived into wholeheartedly is prediction markets, and like that mid-August crypto rally, these have also been hot. America is a nation of gamblers, and we're happy to wager on almost anything under the sun. In collaboration with top prediction markets company Kalshi, Robinhood offers these services on a wide range of events.
Prediction markets have quickly become a crucial revenue stream for Robinhood. In fact, in that second quarter, they generated more revenue than crypto trading fees.
Premium Feature
Moneyball Superscore
81/100
Today's Change
(
16.57
%) $
17.73
Current Price
$
124.72
The great widening Robinhood has broadened its business to the point where it's no longer dependent on one or even two of its activities to keep the growth train running. At the moment, equities, cryptocurrencies, and prediction markets are immensely popular and producing high transaction volumes.
While this won't last forever for all three, Robinhood should still do well if two, or even one, resists falling into a slump. I believe management has done an admirable job not only by bravely embracing the next-generation markets that today's investors are eager to trade, but also by expanding its reach and scope in the process.
This is an exciting company, and one that I feel has plenty of upside potential with its stock.
BEST a Luvata uzavřely strategickou spolupráci na dodávkách vysoce výkonných RRP supravodičů pro projekty magnetického fúzního zadržování. Cílem je posílit globální výrobní kapacitu a odolnost dodavatelského řetězce.
RRP Preferred for High-Field Demonstration and First-of-a-Kind Power Plant Opportunities
HANAU, Germany--(BUSINESS WIRE)--Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (Nasdaq: BRKR), and Luvata Materials & Solutions, a Business Unit of Luvata Group (LUVATA) today announced a strategic collaboration to support the rapidly growing demand for superconducting materials and technologies required by next-generation magnetic confinement fusion power demonstration plant projects worldwide.
The BEST-LUVATA collaboration aims to further strengthen and expand industrial readiness and availability of high-performance RRP superconductors to significantly upscale global manufacturing capacity, enhance supply chain flexibility and resilience, and to increase industry's ability to meet the demanding requirements of large-scale, high-field magnetic confinement fusion programs.
Clean, safe and inexhaustible fusion energy has generated unprecedented interest in recent years to power AI, GDP growth and human technological and industrial activities for the future. The most mature fusion technologies require superconductors to confine the energy-producing plasma, which is hotter than the core of the sun. Next-generation RRP superconductors are ideally suited for large and critical projects involving tokamaks and stellarators because of their high-performance, high-current carrying capacity, robustness and materials strength, and availability in industrial quantities.
RRP stands for Rod-Restack Process, an advanced manufacturing technology to produce highest performance niobium-tin (Nb3Sn) superconducting wires with high critical current density (Jc) for high magnetic fields of 12 to 20 Tesla. RRP superconductors have been successfully deployed in the LHC at CERN, in ultra-high field NMR magnets, and in high-field magnet tokamak fusion projects.
Both BEST and LUVATA have extensive experience in advanced superconducting applications and a strong track record of supporting landmark fusion projects worldwide. Together, they previously contributed materials, manufacturing expertise, and technological know-how to major international programs, such ITER (International Thermonuclear Experimental Reactor) and the Wendelstein 7-X stellarator, the world's most advanced superconducting plasma physics facilities.
"The future of fusion energy will depend not only on scientific breakthroughs, but also on the availability of a robust industrial ecosystem capable of delivering reliable high-performance superconductor products at scale," said Dr. Burkhard Prause, President & Chief Executive Officer of Bruker Energy and Supercon Technologies. "By leveraging our complementary capabilities at scaling production for our high-performance and proven RRP superconductors, we aim to further strengthen global superconducting supply chains and support our fusion project customers worldwide."
Major fusion programs are underway in Europe, America, China, Japan, and South Korea. These initiatives are driving demand for proven, robust superconducting technologies and experienced large-scale manufacturing partners. The upcoming high-field tokamak and stellarator demand will surpass previous large projects, which were aimed at advancing plasma physics and fusion pilot know-how. For example, Gauss Fusion is evaluating RRP for its high-field stellarator Gauss Industrial Demonstrator and its GIGA fusion power plant platform.
"The fusion sector is entering an exciting phase of growth and industrialization," said Dr. Antti Kilpinen, Executive Vice President – Superconductors, at Luvata Materials & Solutions. "The emergence of large-scale fusion programs creates a significant opportunity for experienced industrial partners to contribute to the fusion energy industry's development. Together, we aim to strengthen the availability of reliable superconductors for customer success in executing ambitious fusion energy projects."
About Bruker Energy & Supercon Technologies (BEST)
BEST, together with Research Instruments GmbH (RI), is the deep-tech segment of Bruker Corporation (Nasdaq: BRKR) focused on advanced superconductors and superconducting solutions, on enabling fusioneering and high-energy fundamental physics research and accelerator technologies, as well as on bespoke EUV semiconductor lithography modules. BEST develops and provides high-performance superconductors, including high-performance RRP® conductors, as well as superconducting solutions and key technologies for customers in diverse markets, ranging from life science tools (NMR, EPR, preclinical MRI, gyrotrons, MRMS, other), healthcare (OEM MRI and proton therapy magnets), to magnetic confinement fusion and wind energy demonstrators. BEST is a leading superconducting wire manufacturer, with major manufacturing sites in Germany, the US and the UK. For more than 50 years, our high-performance superconductors have met or exceeded the needs of healthcare, academic and national labs, and deep-tech industrial customers worldwide.
For more information, please visit www.bruker.com.
About Luvata Materials & Solutions (LUVATA)
Luvata Materials & Solutions, a Business Unit of Luvata Group, offers a broad portfolio of highly specialized copper products and superconducting wires that play a vital role in many of today’s fastest-growing industries. We focus on delivering complex, high-quality copper and other metal products, supported by exceptional technical expertise that creates significant value for our customers. Working closely with customers and partners, we develop innovative solutions for industries including science, electronics, power generation and distribution, renewable energy, healthcare, automotive, and metals and mining. Luvata collaborates extensively with fusion energy companies, research institutes, and universities, and is an active member of FinnFusion. Over the years, we have proudly contributed to leading international fusion projects and research facilities, including ITER (International Thermonuclear Experimental Reactor), JET, JT-60, and KSTAR, as well as numerous other publicly funded research programs around the world. Luvata Group is part of Mitsubishi Materials Corporation.
For more information, please visit: www.luvata.com.
Casey’s General Stores, Inc. (NASDAQ:CASY) will release its first earnings report after the closing bell on Tuesday, Sept. 8.
Analysts expect the Ankeny, Iowa-based company to report quarterly earnings of $6.81 per share, up from $5.77 per share in the year-ago period. The consensus estimate for Casey’s quarterly revenue is $5.56 billion. It reported $4.57 billion last year, according to Benzinga Pro.
On June. 9, Caseys General Stores reported better-than-expected fourth-quarter financial results.
Casey’s shares rose 0.6% to close at $758.42 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
UBS analyst Mark Carden maintained a Neutral rating and cut the price target from $945 to $925 on Aug. 27, 2026. This analyst has an accuracy rate of 68%. BMO Capital analyst Kelly Bania upgraded the stock from Market Perform to Outperform rating with a price target of $950 on June 29, 2026. This analyst has an accuracy rate of 67%. BNP Paribas analyst Steve McManus maintained an Outperform rating and raised the price target from $995 to $1,030 on June 25, 2026. This analyst has an accuracy rate of 71%. Goldman Sachs analyst Bonnie Herzog maintained a Neutral rating and boosted the price target from $695 to $795 on June 25, 2026. This analyst has an accuracy rate of 64%. RBC Capital analyst Irene Nattel maintained a Sector Perform rating and increased the price target from $794 to $850 on June 25, 2026. This analyst has an accuracy rate of 56%. Trending
Considering buying CASY stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Dozorčí rada Volkswagenu jednomyslně schválila plán do roku 2030, který má zvýšit efektivitu a konkurenceschopnost. Počítá i s dalším zrušením zhruba 50 000 pracovních míst po celém světě do konce desetiletí.
Dozorčí rada německé automobilky Volkswagen dnes jednomyslně schválila rozsáhlý plán budoucnosti firmy do roku 2030, jehož cílem je transformace společnosti, zvýšení její efektivity a konkurenceschopnosti. Mimo jiné plánuje Volkswagen do konce desetiletí zrušit po celém světě dalších zhruba 50.000 pracovních míst. Volkswagen o rozhodnutí informoval v tiskové zprávě. Plán označuje za nejzásadnější transformační program ve své historii.
Schválení plánu přichází v době, kdy Volkswagen čelí tlaku na snižování nákladů a zvyšování efektivity. Plán má 12 iniciativ, jejichž cílem je posílit odolnost a konkurenceschopnost koncernu a jeho značek v podmínkách silného konkurenčního tlaku.
Snížení počtu pracovních míst o 50 000 je nad rámec již dohodnutých 50 000, celkem tak bude zrušeno 100 000 pracovních míst, což představuje zhruba 15 procent celosvětového počtu zaměstnanců. Podle agentury AFP je to největší restrukturalizace, jaká byla v globálním automobilovém průmyslu uskutečněna. Úprava počtu zaměstnanců po celém světě je podle koncernu nezbytná k dosažení cílů transformačního programu. Volkswagen zatím neuvedl, kdy by se případné propouštění mělo uskutečnit, ani jak se rozdělí mezi jednotlivé značky a regiony.
V koncernu je nyní ohrožena budoucnost čtyř německých závodů. Pro továrny v Emdenu, Cvikově, Hannoveru a Neckarsulmu zatím nelze zaručit konkurenceschopnou navazující výrobu, která by po skončení současných výrobních programů zajistila jejich další využití. Týká se to jednotlivých závodů postupně v letech 2031 až 2034. Volkswagen zároveň uvedl, že pro všechny čtyři lokality prověřuje také alternativní možnosti využití.
Koncern Volkswagen má v současnosti v Německu deset továren, v nichž se vyrábějí vozy značky Volkswagen, dva závody značky Audi a dvě výrobní továrny automobilky Porsche. V Německu koncern zaměstnává přes 280.000 lidí. Po celém světě má přes stovku závodů a přibližně 663.000 zaměstnanců.
Součástí koncernu je i český podnik Škoda Auto. V červenci Škoda uvedla, že restrukturalizační plán koncernu nemá přímý dopad na její aktivity.
V polovině loňského prosince ukončil po 24 letech provoz závod Volkswagenu v Drážďanech. Bylo to tehdy poprvé v 88leté historii, kdy Volkswagen uzavřel některou ze svých továren v Německu. Takzvaná Skleněná manufaktura se teď mění na centrum inovací. Změna výroby by mohla zachránit i továrnu v Osnabrücku, která by se do budoucna měla zaměřit na produkci pro obranný průmysl.
Studsvik uzavřel dohodu s GE Vernova Hitachi Nuclear Energy a Samsung C&T o rozvoji prvního projektu nových jaderných bloků ve Švédsku o výkonu 1,2 GW. První jednotka BWRX-300 má být zprovozněna v polovině 30. let.
Following a competitive evaluation process, Studsvik has selected GE Vernova Hitachi Nuclear Energy and Samsung C&T as its strategic partners for the first project to build new nuclear power, either at its existing licensed nuclear site in or at the Målma site in Valdemarsvik. Together with GE Vernova Financial Services and DS Investment Partners, the companies will advance an initial four-unit BWRX-300 project in Sweden, totalling 1.2 GW of new nuclear generating capacity, with the first unit expected in operation in the mid-2030s. /PRNewswire/ -- Studsvik AB (publ), GE Vernova Hitachi Nuclear Energy, GE Vernova Financial Services, DS Investment Partners and Samsung C&T today announced an agreement to advance the ReFirm nuclear programme at Studsvik's sites in Sweden. The agreement is exclusive for a fixed period, which the parties may extend.
ReFirm is a multi-site small modular reactor (SMR) and new nuclear development program that became part of the Studsvik Group through the acquisition of Kärnfull Next (KNXT) earlier this year. KNXT has worked with GE Vernova Hitachi on BWRX-300 deployment in Sweden since 2022 and entered a strategic teaming agreement with Samsung C&T in December 2024. Today's announcement covers sites at Nyköping and Valdemarsvik and provides for development to commence with a four-unit BWRX-300 project of approximately 1,200 MWe in total at one of them.
At Nyköping, Studsvik operates an existing licensed nuclear facility. At Valdemarsvik, an application was submitted in March 2026, the first made under Sweden's new legislation requiring government approval for nuclear facilities. Which site hosts the first project will be decided during the development work.
The phased, multi-unit structure is intended to support standardisation across the programme and creates opportunities to capture lessons learned from early deployment and apply them to subsequent units, helping improve cost, schedule and productivity outcomes.
It will also help maximise Swedish industrial participation throughout engineering, procurement, construction, and long-term operations. This reflects the broader objective of building a supply chain that can support not only the first project, but also follow-on units and wider deployment opportunities in Sweden and Europe.
Studsvik has worked in nuclear technology for more than 75 years, and that capability is what a new plant needs to get through design, qualification and commissioning. Beyond any equity participation, a domestic new-build programme of this scale is expected to create long-term opportunities for Studsvik's services over the operating life of the plants.
The agreement marks the next phase of development and does not constitute a final investment decision or authorisation to construct. The parties will begin joint development work immediately, including commercial, technical, regulatory and financing activities during the exclusivity period.
Studsvik leads permitting, the environmental impact assessment, site rights, community engagement and the dialogue with the Swedish state. GE Vernova Hitachi leads reactor design, licensing support and cost estimation and acts as design authority, and, together with Samsung C&T, acts as the execution team, giving the project single-point responsibility for design and construction delivery. During the exclusivity period, DS Investment Partners, a South Korean investment firm, will lead the investment and GE Vernova Financial Services participates in an advisory and financial structuring capacity in support of the consortium.
A joint project company will be established to support development, financing, construction, ownership and operation of the plants, with details to be finalised in definitive agreements.
Sweden is expanding nuclear capacity under legislation in force since 2026 that permits reactors at sites beyond the three existing plants and requires government approval for each, supported by a state financing framework of loans and two-way contracts for difference.
"Sweden's electricity supply is a long-term play: existing nuclear capacity is ageing, and demand for baseload power is growing. To meet that, we have looked for long-term partners and for the conditions that let projects like this succeed. In GE Vernova Hitachi and Samsung C&T we have found them. We intend to build the first project either on an existing nuclear site or on greenfield. One reactor is a project. Four is the start of an industry."
- Karl Thedéen, President and Chief Executive Officer, Studsvik
"Today's announcement is about helping Sweden turn its energy ambitions into reality in a timeframe that matters for its communities and industries. The country has a strong foundation of nuclear expertise and operational excellence, and the BWRX-300 combines proven boiling water reactor technology with the lessons being learned every day at the Darlington New Nuclear Project in Canada. Together with a growing global pipeline of projects across North America and Europe, this experience gives Sweden access to a technology that is moving from first-of-a-kind deployment toward fleet-scale execution."
- Jason Cooper, Chief Executive Officer, GE Vernova Hitachi Nuclear Energy
"Samsung C&T is honoured to partner with Studsvik, GE Vernova Hitachi and the other members of the development team to support Sweden's next generation of nuclear energy. By combining proven technology, world-class EPC execution, operational excellence and financing capability, we are establishing a strong foundation for the successful development of the ReFirm programme. We are equally committed to strengthening Sweden's industrial capability, expanding local supply chains and building a long-term strategic partnership that creates lasting value for Studsvik and Sweden."
- Oh Se-chul, President and Chief Executive Officer, Engineering & Construction Group, Samsung C&T
Today's announcement is not expected to have any material financial impact on the Studsvik Group's earnings for 2026.
About Studsvik
Studsvik is an independent nuclear technology company active across the full nuclear lifecycle, from new build development to existing fleet services, operations support and decommissioning. It is a leading supplier of vendor-independent reactor analysis software, and its hot cell laboratories in Nyköping test fuel and materials for fission and fusion applications worldwide. Studsvik also provides radiation protection services and technology for treating radioactive waste, and handles and packages radioisotopes for healthcare and industry. ReFirm is Studsvik's platform for new nuclear development in Sweden. Founded in 1947 as the centre of Sweden's national nuclear programme, Studsvik today serves operators, fuel vendors, technology developers and regulators in more than 20 countries, has approximately 540 employees in six countries, and is listed on Nasdaq Stockholm (SVIK).
About Samsung C&T
Samsung C&T's Engineering & Construction Group has more than 40 years of engineering and construction experience operating throughout the world. The group spans commercial and residential buildings, civil infrastructure and plant construction. Its landmark projects include Burj Khalifa, the world's tallest building, the ongoing Riyadh Metro Project in Saudi Arabia, the Qurayyah 4,000MW CCPP Project, and the ongoing Qatar 2,000MW Solar Power Project. In the nuclear energy sector, the company has successfully delivered 12GW across 10 units, including the 5.6GW Barakah Nuclear Power Plant in the UAE. It has recently undertaken the Nuclear Power Plant refurbishment project and Front-End Engineering Design (FEED) for Small Modular Reactors (SMRs), demonstrating its global competitiveness in large-scale reactor and SMR technologies, and solidifying its expertise across all areas of the nuclear industry.
About GE Vernova Hitachi
GE Vernova's Nuclear energy business, through its global alliance with Hitachi Ltd., is a world-leading provider of nuclear services and advanced nuclear reactor designs. Technologies include boiling water reactors and small modular reactors, such as the BWRX-300, which is one of the simplest, yet most innovative boiling water reactor designs. GE Vernova's Nuclear fuel business, Global Nuclear Fuel (GNF), is a world-leading supplier of boiling water reactor fuel and fuel-related engineering services. GNF is a GE Vernova-led joint venture with Hitachi, Ltd. and operates primarily through Global Nuclear Fuel-Americas, LLC in Wilmington, N.C., and Global Nuclear Fuel-Japan Co., Ltd. in Kurihama, Japan. HITACHI is a trademark of Hitachi, Ltd. used under trademark license. GE is a trademark of General Electric Company used under trademark license.
About DS Investment Partners
DS Investment Partners (DSIP) is a Seoul-based investment firm focused on energy, technology, healthcare and strategic infrastructure sectors. Working alongside technology providers, industrial partners and institutional investors across Asia, the Middle East, Europe and North America, DSIP seeks to support investments that enhance security, reliability and long-term sustainability while creating value for stakeholders.
About GE Vernova
GE Vernova Inc. (NYSE: GEV) is a purpose-built global energy company that includes Power, Wind, and Electrification segments and is supported by its accelerators. Building on over 130 years of experience tackling the world's challenges, GE Vernova is uniquely positioned to help lead the energy transition by continuing to electrify the world while simultaneously working to decarbonize it. GE Vernova helps customers power economies and deliver electricity that is vital to health, safety, security, and improved quality of life. GE Vernova is headquartered in Cambridge, Massachusetts, U.S., with approximately 75,000 employees across 100+ countries around the world. Supported by the Company's purpose, The Energy to Change the World, GE Vernova technology helps deliver a more affordable, reliable, sustainable, and secure energy future.
GE Vernova's Financial Services business provides customers with a suite of financing solutions for projects that aim to accelerate a new era of energy. It has deployed sizeable capital into energy projects globally through development financing, direct equity investments, and capital raising from private and public financial institutions.
Disclosure
This information is information that Studsvik AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation and Sweden's Securities Markets Act. The information was released for public disclosure, through the agency of the contact person above, on 3 September 2026 at 07:30 CEST.
Forward-Looking Statements
Studsvik: This press release contains statements regarding future circumstances, including the timing of investment decisions, capacity, permitting processes and financing. Such statements are subject to uncertainty and actual outcomes may differ materially from those expressed or implied.
GE Vernova: This document contains forward-looking statements, that is, statements related to future events that by their nature address matters that are, to different degrees, uncertain. These forward-looking statements often address GE Vernova's expected future business and financial performance and financial condition, and the expected performance of its products, the impact of its services and the results they may generate or produce, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "estimate," "forecast," "target," "preliminary," or "range." Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about planned and potential transactions, investments or projects and their expected results and the impacts of macroeconomic and market conditions and volatility on the Company's business operations, financial results and financial position and on the global supply chain and world economy.
For more information, please contact
Karl Thedéen, President and Chief Executive Officer, Studsvik AB (publ), +46 155 22 10 00
Media enquiries: [email protected]
This information was brought to you by Cision http://news.cision.com
FDA schválila ZANVASTRO od Ionis Pharmaceuticals jako první a jedinou léčbu měnící průběh Alexanderovy choroby u dětí i dospělých. Léčba byla podpořena studií, která splnila hlavní cíl.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved ZANVASTRO™ (zilganersen) for the treatment of Alexander disease (AxD) in pediatric and adult patients. ZANVASTRO is the first and only disease modifying treatment for AxD, an ultra-rare, progressive and often fatal neurological disorder that can affect motor, cognitive, autonomic and gastrointestinal function. Until now, treatment of AxD has primarily been limited to managing symptoms. ZANVASTRO is an RNA-targeted medicine designed to address the underlying disease mechanism of AxD by reducing the production of glial fibrillary acidic protein (GFAP). ZANVASTRO 50 mg is administered quarterly as an intrathecal (IT) injection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903826844/en/
ZANVASTRO (zilganersen) logo
“Today’s approval of ZANVASTRO begins a new chapter for people living with Alexander disease and their families, who have long faced this relentlessly progressive and often fatal disease with no treatment options,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “This transformative approval also marks our first independent launch from our industry-leading neurology pipeline and underscores the power of our RNA-targeted technology to address serious neurological diseases without adequate treatment options. We are proud to bring this important new treatment to this incredible community and are deeply grateful to the clinical trial participants and their families, regulators, investigators and advocates who helped make this advancement possible.”
AxD affects approximately 1 in 1 to 3 million people worldwide. Initial signs of AxD can present from infancy through adulthood and may vary depending on age of onset. As AxD progresses, symptoms may include progressive motor and cognitive dysfunction, a loss of independence and the inability to control muscles for swallowing, airway protection and purposeful movements. AxD is caused by changes in the GFAP gene that lead to the overproduction and toxic accumulation of GFAP in astrocytes. Over time, dysfunction in astrocytes can damage neurons and myelin, which can lead to symptoms commonly associated with AxD.
“For decades, care for people living with Alexander disease has focused primarily on managing symptoms, without an option to modify the underlying cause of disease,” said Amy Waldman, M.D., M.S.C.E., pediatric neurologist and lead investigator for the ZANVASTRO study at Children’s Hospital of Philadelphia. “The approval of ZANVASTRO for the treatment of Alexander disease represents a significant advancement in care and opens new possibilities for patients and their families. For the first time, we can move beyond managing individual manifestations of the disease to addressing its underlying biology, with the potential to meaningfully improve outcomes for this community.”
“As a mom to a young boy living with Alexander disease and an advocate for this community, I have seen firsthand the profound impact this disease has on individuals and their families. Today’s approval represents a fundamental shift, changing the conversation from ‘How do we manage this disease’ to ‘How can we treat it,’” said Emily Petty, president, End Alexander Disease. “For far too long, receiving a diagnosis of Alexander disease was accompanied by uncertainty and the difficult reality that there were no available treatments. Today, that begins to change. ZANVASTRO marks a defining moment and brings a new sense of possibility to our community.”
The FDA approval was based on positive results from the pivotal study of ZANVASTRO in people living with AxD. The pivotal study met its primary endpoint in individuals ≥ 5 years of age, with ZANVASTRO 50 mg demonstrating statistically significant and clinically meaningful stabilization of gait speed as assessed by the 10-Meter Walk Test (10MWT), a commonly used measure of gross motor function in neurologic disease, compared to control at Week 61 (least square mean difference 33.3%, p=0.041). ZANVASTRO also demonstrated improvement in gross motor function in patients 2 to 4 years of age as assessed by the Gross Motor Function Measure-88 (GMFM-88), a well-established motor endpoint, compared to control at Week 61. Secondary and exploratory endpoint results from patient/caregiver- and clinician-reported outcome assessments consistently favored ZANVASTRO.
ZANVASTRO demonstrated a favorable safety and tolerability profile, with most adverse events (AEs) being mild or moderate in severity. Serious treatment-emergent adverse events (TEAEs) occurred less frequently in the ZANVASTRO group compared to control.
Ionis is committed to helping people access the medicines they are prescribed and will offer a full suite of services for people prescribed ZANVASTRO through Ionis Every Step™. As part of Ionis Every Step, patients will have access to a wide range of support and resources including disease state and product education for patients and caregivers, access to a dedicated Patient Education Manager, assistance with the insurance approval process, information on affordability programs and other ongoing services and resources throughout the treatment journey. Visit ZANVASTRO.com for more information.
With the approval of ZANVASTRO, the FDA granted Ionis a Rare Pediatric Disease Priority Review Voucher (PRV), a program designed to incentivize the development of therapies for serious and life-threatening diseases by providing a mechanism to potentially accelerate regulatory review timelines for subsequent applications.
ZANVASTRO will be available in the U.S. in the coming weeks.
In June 2026, Ionis entered into a license agreement with Recordati, a global pharmaceutical company headquartered in Italy, focused on specialty and rare diseases, under which Recordati obtained exclusive rights to develop and commercialize zilganersen in all countries outside the U.S. Ionis is working closely with Recordati on preparing regulatory submissions in Europe and Japan, which are expected in 2027.
Webcast
Ionis will hold a webcast on Friday, Sept. 4 at 10:00 a.m. ET to discuss the FDA approval. Interested parties may access the webcast here. A webcast replay will be available for a limited time.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Aseptic Meningitis
If symptoms consistent with aseptic meningitis develop, diagnostic workup and treatment should be initiated according to the standard of care.
Adverse reactions of aseptic meningitis (also called chemical meningitis or drug-induced aseptic meningitis) were reported in patients treated with ZANVASTRO during the double-blind and open-label periods of Study 1. One patient experienced a serious adverse reaction of aseptic meningitis during the double-blind treatment period of Study 1, which reoccurred in the open-label extension period and required dose interruption and pretreatment with intravenous dexamethasone prior to subsequent administration of ZANVASTRO. Despite corticosteroid premedication, CSF white blood cell (WBC) and protein increased with continued exposure, but the patient remained asymptomatic and did not require discontinuation from treatment. In addition, nonserious adverse drug reactions of CSF WBC increases have also been reported with ZANVASTRO.
ADVERSE REACTIONS
Most common adverse reactions (incidence ≥25% patients treated with ZANVASTRO and greater than control) were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome.
Patients Less Than 2 Years of Age
The adverse reactions of patients less than 2 years of age are expected to be similar to that of pediatric patients 2 years of age and older.
Please see full Prescribing Information for ZANVASTRO.
About the ZANVASTRO Study
The global, multicenter, randomized, double-blind, controlled, multiple-ascending dose (MAD) Phase 1-3 study (NCT04849741) enrolled 54 participants with Alexander disease (AxD) between the ages of 1.5 and 53 years across 13 sites in eight countries. Most participants in the study were children, reflecting the early onset and severe progression of AxD in pediatric populations. Participants were randomized in a 2:1 ratio to receive ZANVASTRO or control for a 60-week double-blind treatment period. The study included two dose cohorts, 25 mg and 50 mg, with the 50 mg dose cohort analyzed as the pivotal dose cohort, with dosing every 12 weeks. At week 60, eligible participants entered a 60-week open-label treatment period, followed by a 120-week open-label long-term extension period. During the long-term extension, participants in the 25 mg dose cohort transitioned to the 50 mg dose cohort. Participants in countries where zilganersen has not been or is not commercially available can continue to receive zilganersen treatment through a 240-week extended long-term extension period, which includes 20 additional doses, followed by a 28-week post-treatment follow-up period. The primary endpoint was percent change from baseline in gait speed as assessed by the 10-Meter Walk Test (10MWT), an assessment of functional mobility, at the end of the double-blind treatment period. Key secondary endpoints include patients' self-identified Most Bothersome Symptom (MBS) Score, change from baseline in Patient Global Impression of Severity (PGIS) Score and Patient Global Impression of Change (PGIC) Score and Clinician Global Impression of Change (CGIC) Score at the end of the double-blind treatment period.
About Alexander Disease (AxD)
AxD is an ultra-rare, progressive and often fatal neurological disease that occurs in approximately 1 per 1 to 3 million people worldwide and affects a type of cell in the brain called astrocytes. Astrocytes have multiple roles in the brain including support of neurons and oligodendrocytes, which maintain the myelin sheath around nerve fibers. AxD is caused by disease-causing variants in the glial fibrillary acidic protein (GFAP) gene and is generally characterized by progressive neurological deterioration resulting in loss of functional mobility, loss of independence and the inability to control muscles for large movements, swallowing and airway protection, though symptoms can vary depending on age of onset. AxD usually leads to death within 14 - 25 years after symptom onset.
About ZANVASTROTM (zilganersen)
ZANVASTROTM (zilganersen)is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alexander disease (AxD) in pediatric and adult patients. ZANVASTRO is an RNA-targeted therapy designed to inhibit production of excess glial fibrillary acidic protein (GFAP) that accumulates as a result of pathogenic variants in the GFAP gene. For more information about ZANVASTRO, visit ZANVASTRO.com.
About Ionis Neurology
Ionis has been at the forefront of discovering and developing leading neurological disease medicines, including ZANVASTROTM (zilganersen), the only approved treatment for Alexander disease, SPINRAZA® (nusinersen), the first approved treatment for spinal muscular atrophy, WAINUA® (eplontersen), a medicine to treat hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), and QALSODY® (tofersen) for SOD1-ALS. The clinical-stage portfolio includes 12 investigational medicines, of which seven are wholly owned by Ionis. Ionis' investigational portfolio includes medicines for which there are few or no disease modifying treatments, such as rare diseases including Angelman syndrome, prion disease and multiple system atrophy, as well as more common conditions like Alzheimer's disease.
About Ionis Pharmaceuticals, Inc.
For more than three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.
Ionis Forward-looking Statements
This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of ZANVASTRO, Ionis' technologies and other products in development and our expectations regarding development and regulatory milestones. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2025, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. ZANVASTROTM and Ionis Every StepTM are trademarks of Ionis Pharmaceuticals, Inc. QALSODY® and SPINRAZA® are registered trademarks of Biogen. WAINUA® is a registered trademark of the AstraZeneca group of companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260903826844/en/
Guidewire Software, Inc. (GWRE) Q4 2026 Earnings Call September 3, 2026 5:00 PM EDT
Company Participants
Alex Hughes - Vice President of Investor Relations
Mike Rosenbaum - CEO & Director
John Mullen - President
Jeffrey Cooper - Chief Financial Officer
Conference Call Participants
Alexei Gogolev - JPMorgan Chase & Co, Research Division
Rishi Jaluria - RBC Capital Markets, Research Division
Joseph Vruwink - Robert W. Baird & Co. Incorporated, Research Division
Dylan Becker - William Blair & Company L.L.C., Research Division
Hoi-Fung Wong - Oppenheimer & Co. Inc., Research Division
J. Lane - Stifel, Nicolaus & Company, Incorporated, Research Division
Allan M. Verkhovski - BTIG, LLC, Research Division
Tamjid Md Moinuddin Chowdhury - Guggenheim Securities, LLC, Research Division
Michael Turrin - Wells Fargo Securities, LLC, Research Division
William Fitzsimmons - Piper Sandler & Co., Research Division
Aaron Kimson - Citizens JMP Securities, LLC, Research Division
Presentation
Operator
Greetings, and welcome to the Guidewire Fourth Quarter Fiscal 2026 Financial Results Conference Call. As a reminder, this call is being recorded and will be posted on our Investor Relations page later today. I would now like to turn the call over to Alex Hughes, Vice President of Investor Relations. Thank you. Alex, you may begin.
Alex Hughes
Vice President of Investor Relations
Thank you, Grace. Hello, everyone. With me today is Mike Rosenbaum, Chief Executive Officer; John Mullen, President; and Jeff Cooper, Chief Financial Officer. Complete disclosure of our results can be found in our press release issued today as well as in our related Form 8-K furnished to the SEC, both of which are available on the Investor Relations section of our website. We have also posted our fourth quarter earnings deck on our IR section of the website. Today's call is being recorded.
A replay will be available following its conclusion. Statements today include forward-looking ones regarding our financial outlook, our cloud and
Douglas Emmett vyhlásila čtvrtletní hotovostní dividendu 0,19 USD na akcii, tedy 0,76 USD anualizovaně. Vyplacena bude 15. října 2026 akcionářům k 30. září 2026.
Douglas Emmett, Inc. (NYSE: DEI), a real estate investment trust (REIT), announced today that its Board of Directors has declared a quarterly cash dividend on each share of its common stock of $0.19, or $0.76 on an annualized basis, to be paid on October 15, 2026 to shareholders of record as of September 30, 2026.
About Douglas Emmett, Inc.
Douglas Emmett, Inc. (DEI) is a fully integrated, self-administered and self-managed real estate investment trust (REIT), and one of the largest owners and operators of high-quality office and multifamily properties located in the premier coastal submarkets of Los Angeles and Honolulu. Douglas Emmett focuses on owning and acquiring a substantial share of top-tier office properties and premier multifamily communities in neighborhoods that possess significant supply constraints, high-end executive housing and key lifestyle amenities. Please visit our website at www.douglasemmett.com for more information about Douglas Emmett.
Safe Harbor Statement
Except for the historical facts, the statements in this press release regarding Douglas Emmett’s business activities are forward-looking statements based on the beliefs of, assumptions made by, and information currently available to us about known and unknown risks, trends, uncertainties and factors that are beyond our control or ability to predict. Although we believe that our assumptions are reasonable, they are not guarantees of future performance and some will inevitably prove to be incorrect. As a result, our actual future results can be expected to differ from our expectations, and those differences may be material. Accordingly, investors should use caution in relying on forward-looking statements to anticipate future results or trends. For a discussion of some of the risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in our Annual Report on Form 10-K for 2025, filed with the U.S. Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260903420079/en/
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Silicon Motion dokončila první fázi programu souladu s EU Cyber Resilience Act a upravila procesy hlášení incidentů i práce s chybami. Jde o přípravný krok před plným uplatněním CRA.
Silicon Motion Technology Corporation (NasdaqGS: SIMO), a global leader in designing and marketing NAND flash controllers for solid-state storage devices, today announced that it has completed the first stage of its compliance program for the European Union Cyber Resilience Act (CRA). Following a comprehensive internal assessment, the company has aligned its product cybersecurity controls and processes with the CRA’s incident-reporting obligations that take effect on September 11, 2026, and has established vulnerability-handling processes covering key areas contemplated by the CRA, as part of its ongoing CRA readiness efforts. This milestone underscores Silicon Motion’s commitment to product security and provides customers with a trusted foundation for addressing evolving cybersecurity requirements for products with digital elements in the European Union. This is a preparatory step ahead of the CRA’s full application on December 11, 2027, and Silicon Motion will continue to evolve its program as remaining implementing guidance and harmonized standards are further developed and finalized.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903878730/en/
Silicon Motion Strengthens Cybersecurity Readiness for the EU Cyber Resilience Act
“As AI expands across data centers, edge devices and Physical AI applications, cybersecurity has become an essential part of product development,” said Wallace C. Kou, President and Chief Executive Officer of Silicon Motion. “This initial CRA compliance milestone demonstrates our strong commitment to product security and our determination to deliver secure products that serve as a trusted foundation for customers to build resilient storage solutions.”
To meet the requirements applicable at this stage, Silicon Motion has strengthened its post-market vulnerability management and incident-reporting processes. Key measures include:
Security management and due diligence for third-party hardware and software componentsContinuous vulnerability monitoring, coordinated disclosure and timely remediationIncident escalation and reporting procedures aligned with CRA notification requirementsDefined security support and vulnerability-handling processes throughout the product lifecycleTo support timely vulnerability handling, Silicon Motion has also established a dedicated security vulnerability reporting channel on its website, enabling customers, end users and other stakeholders to report suspected security issues directly to the company for timely investigation and response.
These measures span Silicon Motion’s full product portfolio, including enterprise SSD controllers, enterprise boot drive solutions, edge SSD controllers, embedded eMMC and UFS controllers, Ferri solutions for automotive and Physical AI, and display interface solutions. By strengthening cybersecurity and vulnerability management across its portfolio, Silicon Motion helps customers build secure solutions and remains committed to aligning its practices with evolving CRA guidance and harmonized standards.
This press release contains statements regarding Silicon Motion’s cybersecurity and regulatory compliance initiatives in preparation for compliance with the CRA; however, these initiatives should not be construed as a representation that Silicon Motion or its products are currently compliant with the CRA. Certain CRA requirements, including applicable specifications and harmonised standards, remain subject to further development, publication, and regulatory guidance.
About Silicon Motion
Silicon Motion Technology Corporation (NasdaqGS: SIMO) is the global leader in supplying NAND flash controllers for solid-state storage devices. The company ships more SSD controllers than any other supplier worldwide for servers, PCs, and other edge devices, and is also the leading merchant provider of eMMC and UFS embedded storage controllers used in smartphones, IoT products, and automotive applications.
Silicon Motion also delivers customized, high-performance controller solutions for enterprise SSDs, enterprise boot drives, edge SSDs, embedded eMMC and UFS devices, and Ferri solutions for automotive and Physical AI applications. Its controllers and storage solutions combine high performance, power efficiency and proven reliability to support AI infrastructure, Edge AI and Physical AI applications.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260903878730/en/
Robinhood (HOOD +16.57%) shares were up about 15% as of this writing Thursday, at about $123.
The jump followed a wave of analyst notes and a record day on its own new blockchain network. Morgan Stanley upgraded the stock Tuesday to overweight from equal weight and lifted its price target to $150 from $124, and more bullish notes followed this week.
Morgan Stanley analyst Michael Cyprys argued that Robinhood's expanding product lineup is producing more activity and more revenue per customer. In plain terms, they're arguing Robinhood is no longer just a trading app.
And Robinhood itself put a number on that idea in late July: 13 business lines that have each reached $100 million or more in annualized revenue.
Since then, network data suggests a 14th has joined the list, and it didn't exist three months ago.
Image source: Getty Images.
The count holds upRobinhood's second-quarter report, released in late July, showed record revenue of $1.31 billion, up 32% year over year, and net income up 48% (helped by one-time investment gains). Chief financial officer Shiv Verma said the results reflected the company's product pace, with "Robinhood Legend and the Credit Card business joining our growing roster of now thirteen different business lines that have reached $100 million-plus in annualized revenues."
I count 13 lines in the 10-Q's revenue table that annualize above $100 million (anything above $25 million in the quarter). They span options, event contracts, cryptocurrencies, and equities, five interest-based lines led by margin lending, Gold subscriptions, proxy services, and two catch-all "other" buckets. The company's list is built on products rather than filing line items (Robinhood Legend doesn't get its own row), but both counts land at 13.
Lines can fall off the list, too. Securities lending was above the bar a year ago, at $54 million in the quarter, and produced just $10 million in this one.
How big is the newest line?The 14th didn't appear in any of those documents. It barely existed when they were filed.
Robinhood Chain, the company's own blockchain network built for real-world assets such as tokenized stocks, went live on July 1 -- one day after the second quarter ended.
Not only did the network set a fee record of about $3.8 million on Tuesday, but it also collected more than the Ethereum and Base networks that day. It broke that record Wednesday at about $4.5 million, according to DefiLlama data. Its average daily fee pace over the past 30 days now annualizes to about $179 million.
That $179 million needs two adjustments. Robinhood sends about 10% of the network's revenue after costs back to the Arbitrum ecosystem, whose technology the chain runs on. And annualizing the hottest stretch of a two-month-old network is generous math -- the chain's lifetime revenue through the start of this week was only about $10 million, and daily fees that spike may fade just as quickly.
Even with those adjustments, the pace arguably clears $100 million. Zoom out, though, and it amounts to about 2% of Robinhood's revenue pace of roughly $5.2 billion. Big enough to make the list, and far too small to carry the company.
Order flow still supplies a third of revenueHow much of the company still runs on its best-known business, routing customers' stock and options trades to market makers?
In the second quarter, equities produced $129 million of transaction revenue and options $342 million. Together, the two lines produced about 36% of total revenue.
But that share isn't shrinking. A year earlier, the two supplied about a third of revenue as well, and both are still growing. Equities transaction revenue nearly doubled year over year, while options revenue rose 29%.
The diversification is happening elsewhere. Cryptocurrency trading revenue was $160 million a year ago, $134 million in the first quarter, and $100 million in the second -- a steady step down. Meanwhile, event contracts (Robinhood's prediction-markets business) went from $10 million a year ago to $104 million in the first quarter and then $156 million in the latest one, and margin interest nearly doubled to $215 million.
Premium Feature
Moneyball Superscore
81/100
Today's Change
(
16.57
%) $
17.73
Current Price
$
124.72
Ultimately, the case under this week's upgrades mostly checks out against Robinhood's own disclosures. The valuation is where I hesitate.
After Thursday's jump, shares cost about 43 times the earnings analysts expect the company to generate next year, while brokerage peer Charles Schwab costs about 14 times its own next-year forecast. Of course, some premium is deserved. After all, Schwab isn't growing revenue 32% or adding two new $100 million lines in a single quarter.
However, higher price targets aren't a reason to buy a stock, and neither is a 15% pop. I wouldn't sell a business that keeps adding $100 million lines. But I wouldn't chase the growth stock here, either. I view it as a hold for now.
UiPath, Inc. (PATH) Q2 2027 Earnings Call September 3, 2026 5:00 PM EDT
Company Participants
Allise Furlani - Senior Director of Investor Relations
Daniel Dines - Co-Founder, CEO, & Executive Chairman of the Board
Ashim Gupta - CFO & COO
Hitesh Ramani - Deputy CFO & Chief Accounting Officer
Conference Call Participants
Sanjit Singh - Morgan Stanley, Research Division
Bryan Bergin - TD Cowen, Research Division
Scott Berg - Needham & Company, LLC, Research Division
Jacob Zerbib - William Blair & Company L.L.C., Research Division
Raimo Lenschow - Barclays Bank PLC, Research Division
Terrell Tillman - Truist Securities, Inc., Research Division
Sanika Merchant - RBC Capital Markets, Research Division
Presentation
Operator
Good day, everyone. My name is Megan, and I will be your conference operator today. At this time, I would like to welcome you to the UiPath Second Quarter 2027 Earnings Conference Call. [Operator Instructions] At this time, I would like to turn the call over to Allise Furlani, Vice President of Investor Relations.
Allise Furlani
Senior Director of Investor Relations
Good afternoon, and thank you for joining us today to review UiPath's second quarter fiscal 2027 financial results, which we announced in our earnings press release issued after the close of the market today. On the call with me are Daniel Dines, Founder and Chief Executive Officer; Ashim Gupta, Chief Operating Officer; and Hitesh Ramani, Chief Financial Officer, to deliver our prepared comments and answer questions. Our earnings press release and financial supplemental materials are posted on the UiPath Investor Relations website. These materials include GAAP to non-GAAP reconciliations. We will be discussing non-GAAP measures on today's call.
This afternoon's call includes forward-looking statements regarding our financial guidance for the third quarter and full fiscal year 2027, and our ability to drive and accelerate future growth and operational efficiency and grow our platform, product offerings and market
THE WOODLANDS, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 409 homes in August 2026, including 9 currently or previously leased single-family rental homes. This represents a 9.9% increase compared to 372 homes closed in August 2025.
As of August 31, 2026, the Company had 153 active selling communities.
About LGI Homes, Inc.
Headquartered in The Woodlands, Texas, LGI Homes, Inc. is a pioneer in the homebuilding industry, successfully applying an innovative and systematic approach to the design, construction and sale of homes across 36 markets in 21 states. LGI Homes has closed over 80,000 homes since its founding in 2003 and has delivered profitable financial results every year. Nationally recognized for its quality construction and exceptional customer service, LGI Homes was named to Newsweek’s list of the World’s Most Trustworthy Companies. LGI Homes’ commitment to excellence extends to its employees, earning the Company numerous workplace awards at the local, state, and national level, including the Top Workplaces USA 2026 Award. For more information about LGI Homes and its unique operating model focused on making the dream of homeownership a reality for families across the nation, please visit the Company’s website at www.lgihomes.com.
CONTACT:
Joshua D. Fattor
Executive Vice President of Finance and Capital Markets
Head of Investor Relations
(281) 210-2586 [email protected]
lululemon athletica inc. uspořádala konferenční hovor k výsledkům za 2. čtvrtletí 2026. V úvodu zaznělo pouze upozornění na výhledová prohlášení a rizika s nimi spojená.
lululemon athletica inc. (LULU) Q2 2026 Earnings Call September 3, 2026 4:30 PM EDT
Company Participants
Howard Tubin - Vice President of Investor Relations
Meghan Frank - Interim Co-CEO & CFO
Andre Maestrini - Interim Co-CEO, President & Chief Commercial Officer
Conference Call Participants
Alexandra Straton - Morgan Stanley, Research Division
Irwin Boruchow - Wells Fargo Securities, LLC, Research Division
Matthew Boss - JPMorgan Chase & Co, Research Division
Lorraine Maikis - BofA Securities, Research Division
Michael Binetti - Evercore ISI Institutional Equities, Research Division
Paul Lejuez - Citigroup Inc., Research Division
Adrienne Yih-Tennant - Barclays Bank PLC, Research Division
Dana Telsey - Telsey Advisory Group LLC
Mark Altschwager - Robert W. Baird & Co. Incorporated, Research Division
Presentation
Operator
Thank you for standing by. This is the conference operator. Welcome to the lululemon athletica inc. Second Quarter 2026 Earnings Conference Call. [Operator Instructions] The conference is being recorded. [Operator Instructions]
I would now like to turn the conference over to Howard Tubin, Vice President, Investor Relations for lululemon athletica. Please go ahead.
Howard Tubin
Vice President of Investor Relations
Thank you, and good afternoon. Welcome to lululemon's second quarter earnings conference call. Joining me today are Meghan Frank, Interim Co-CEO and CFO; and Andre Maestrini, interim Co-CEO, President and Chief Commercial Officer.
Before we get started, I'd like to take this opportunity to remind you that our remarks today will include forward-looking statements reflecting management's current forecast of certain aspects of lululemon's future. These statements are based on current information, which we have assessed, but by which its nature is dynamic and subject to rapid and even abrupt changes. Actual results may differ materially from those contained in or implied by these forward-looking statements due to risks and uncertainties associated with our business, including those we have disclosed in our most recent filings with the SEC including our annual report on Form 10-K
Dylan Becker - William Blair & Company L.L.C., Research Division
Michael Turrin - Wells Fargo Securities, LLC, Research Division
Aleksandr Zukin - Wolfe Research, LLC
Matthew Hedberg - RBC Capital Markets, Research Division
Matthew Martino - Goldman Sachs Group, Inc., Research Division
S. Kirk Materne - Evercore ISI Institutional Equities, Research Division
Matthew Bullock - BofA Securities, Research Division
Nicholas Altmann - BTIG, LLC, Research Division
Mark Schappel - Loop Capital Markets LLC, Research Division
Jason Celino - KeyBanc Capital Markets Inc., Research Division
Isabella Camaj - JPMorgan Chase & Co, Research Division
Presentation
Unknown Executive
[Presentation]
Good afternoon. Welcome to Samsara's Second Quarter Fiscal 2027 Earnings Call. I'm Marty Winick, Director of Finance and Strategy at Samsara. Joining me today are Samsara's Chief Executive Officer and Co-Founder, Sanjit Biswas; and our Chief Financial Officer, Dominic Phillips. In addition to our prepared remarks on this call, additional information can be found in our shareholder letter, press release, investor presentation and SEC filings on our Investor Relations website at investors.samsara.com.
The matters we'll discuss today include forward-looking statements. Actual results may differ materially from those contained in the forward-looking statements and are subject to risks and uncertainties described more fully in our SEC filings. Any forward-looking statements that we make on this call are based on assumptions as of today, September 3, 2026, and we undertake no obligation to update these statements as a result of new information or future events unless required by law.
During today's call, we will discuss our second quarter fiscal 2027 financial results. We'd like to point out that the company reports non-GAAP results in addition to and not as a substitute for or superior
Cleo Palmer-Poroner - Director of Investor Relations
William Marshall - Co-Founder, CEO & Chairman of the Board
Ashley Whitfield Johnson - President & CFO
Conference Call Participants
Xin Yu - Deutsche Bank AG, Research Division
John Godyn - Citigroup Inc., Research Division
Mike Latimore - Northland Capital Markets, Research Division
Trevor Walsh - Citizens JMP Securities, LLC, Research Division
Ryan Koontz - Needham & Company, LLC, Research Division
Michael Filatov - Joh. Berenberg, Gossler & Co. KG, Research Division
Daniel Hibshman - Craig-Hallum Capital Group LLC, Research Division
Noah Poponak - Goldman Sachs Group, Inc., Research Division
Kyle Benvenuto - Morgan Stanley, Research Division
Gregory Pendy - Clear Street LLC., Research Division
Gabriel Flouret - Cantor Fitzgerald & Co., Research Division
Christopher Quilty - Quilty Space Inc., Research Division
Presentation
Operator
Thank you for joining us, and welcome to the Planet Labs PBC Second Quarter of Fiscal Year 2027 Earnings Call. [Operator Instructions]
I will now hand the conference over to Cleo Palmer-Poroner, Director of Investor Relations.
Cleo Palmer-Poroner
Director of Investor Relations
Thanks, operator, and hello, everyone. I'm joined by Will Marshall and Ashley Johnson, who will provide a recap of our results and discuss our current outlook. We encourage everyone to please reference the earnings press release and earnings update presentation for today's call, which are available on our Investor Relations website.
Before we begin, we'd like to remind everyone that we will make forward-looking statements related to future events or our financial outlook. Any forward-looking statements are based on management's current outlook, plans, estimates, expectations, and projections. The inclusion of such forward-looking information should not be regarded as a representation by Planet that future plans, estimates, or expectations will be achieved. Such forward-looking statements are subject to various risks and uncertainties and assumptions as detailed in our SEC filings, which can be found
Gregory Baszucki, a member of the Board of Directors at Roblox Corporation (RBLX +0.73%), executed a sale of 16,666 shares of Class A Common Stock on September 1, 2026, according to a recent SEC Form 4 filing.
Transaction summaryMetricValueTransaction value~$674,000Shares sold (indirectly held)16,666Post-transaction shares (total)~11.9 millionPost-transaction shares (directly held)3,889Post-transaction shares (indirectly held)~11.9 millionPost-transaction value$485.96 millionTransaction value based on SEC Form 4 weighted average sale price ($40.47); post-transaction value based on September 1, 2026 market close ($40.67).
Key questionsHow does the director's total equity position compare to the reported transaction?
Following the disposition of 16,666 shares, Gregory Baszucki maintains a substantial equity position of ~11.9 million shares, meaning the recent sale impacted less than 1% of his total reported stake.What specific entities hold the remaining indirect shares?
The insider's indirect holdings are distributed across several vehicles, including the Greg and Christina Baszucki Living Trust, a Roth IRA, the Morningstar Dynasty Trust, and the Crossbow Dynasty Trust.Are there other forms of equity compensation associated with the director?
Gregory Baszucki also holds derivative securities in the form of restricted stock units, with each unit representing a contingent right to receive one share of Class A Common Stock.What is the current financial context of the company?
Roblox Corporation reported trailing twelve-month revenue of $5.7 billion and a net income of -$1 billion as of the most recent reporting period, while the stock has seen a -67% one-year return as of the September 1, 2026 market close.Company OverviewMetricValueShare Price (as of market close 2026-09-01)$40.67Market Capitalization$29.2 billionRevenue (TTM)$5.7 billionNet Income (TTM)-$1.0 billionCompany SnapshotRoblox Corporation operates a comprehensive digital entertainment ecosystem centered on Roblox Studio, a free suite of development tools enabling creators to build, deploy, and manage interactive 3D environments, with users accessing these experiences through the Roblox Client application.The company generates revenue through a dual-monetization model leveraging user engagement on its platform, including in-app purchases, developer exchange programs, and premium subscription offerings that create value across both creators and consumers.The platform serves a diverse user base spanning casual gamers, professional developers, educational institutions, and enterprises, with particular strength in attracting younger demographics while expanding into enterprise and educational verticals through Roblox Education.Roblox Corporation operates one of the world's largest user-generated content platforms, with a trailing 12-month revenue base of $5.7 billion reflecting substantial scale in the digital entertainment sector. The company's competitive differentiation stems from its accessible development tools, expansive creator ecosystem, and cross-platform accessibility, positioning it as a significant player in the metaverse and interactive entertainment space.
Despite current profitability headwinds reflected in trailing 12-month net losses, the platform's user engagement metrics and developer network represent substantial strategic assets in the evolving digital entertainment landscape.
What this transaction means for investorsDirector Gregory Baszucki's September 1 sale of Roblox stock occurred after shares had fallen a whopping 67% over the trailing 12 months. However, the disposition was executed as part of a pre-established Rule 10b5-1 plan adopted on November 28, 2025, making this a non-discretionary transaction.
Such plans allow insiders to sell shares at predetermined times to avoid concerns of trading on non-public information. Therefore, Baszucki's sale does not suggest a bearish outlook toward Roblox. Given he retains nearly 12 million shares post-transaction, his massive equity stake ensures his continued alignment with shareholder interests.
Roblox's stock is down because the company's second quarter earnings report suggests tough times ahead. Management provided weak bookings guidance for Q3 that points to as much as an 18% year-over-year drop. A lack of a full-year revenue outlook also cast a cloud over the stock.
Algorithm changes affected the kinds of video games the Roblox platform recommended to users, reducing revenue opportunities in the short term, but the company believes the changes will pay off over the long run. Roblox also implemented stricter child safety tools, which hurt results in the near term yet were necessary to protect younger users.
Stoke Therapeutics a Biogen uvedly, že zorevunersen ve studiích po 4 letech výrazně a trvale snižoval záchvaty u Dravetova syndromu a zlepšoval kognici i chování. Data z fáze 3 EMPEROR se čekají ve 3. čtvrtletí 2027.
–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines–
–New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)–
–Improvements in quality of life were demonstrated through 28 months of treatment–
–Zorevunersen generally well tolerated, with some patients treated for more than 5 years–
–Data from the global, pivotal Phase 3 EMPEROR study anticipated in Q3 2027 to complete the planned rolling U.S. NDA submission to the FDA–
BEDFORD, Mass. and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent seizures as well as significant cognitive and behavioral impairments.
Data presented at EEC represent more than 5 years of clinical experience with zorevunersen in patients with Dravet syndrome, including two Phase 1/2a and ongoing open-label extension studies (OLEs). Four-year OLE results showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior. A new exploratory sub-analysis also showed substantial reductions in the most severe seizure types, which are the leading risk factor for sudden unexpected death in epilepsy (SUDEP)1. SUDEP is the primary cause of premature death in Dravet syndrome2, and up to 20% of children and adolescents with the disease die before reaching adulthood3. An additional sub-analysis presented at EEC demonstrated substantial improvements in quality of life through 28 months in the OLEs. Zorevunersen continues to be generally well tolerated in the OLEs.
“Seizures are the most acute symptom of Dravet syndrome but the disease affects nearly every aspect of a child’s development, from their ability to communicate with loved ones to skills like dressing and feeding themselves,” said Helen Cross, MB ChB, Ph.D., Professor, The Prince of Wales’s Chair of Childhood Epilepsy and Director of University College London Great Ormond Street Institute of Child Health, Honorary Consultant in Paediatric Neurology at Great Ormond Street Hospital. “The continuing improvements in cognition and behavior shown in these studies suggest zorevunersen has the potential to narrow the developmental gap between these children and their neurotypical peers, helping them gain more independence and participate in experiences that many thought might never be possible. Taken together, the data from studies of zorevunersen offer hope for a very different future for people living with Dravet syndrome and their families.”
The global, pivotal Phase 3 EMPEROR study is underway to evaluate the efficacy and safety of zorevunersen. Enrollment has completed in the planned primary analysis population, which will evaluate zorevunersen compared to sham administered via lumbar puncture (LP) in 162 patients enrolled in the U.S., U.K. and Japan. A Phase 3 data readout is anticipated in the third quarter of 2027 to complete the planned rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2027. Enrollment in Europe has also completed with 34 participants enrolled.
Summary of Data from the Phase 1/2a and OLE Studies Presented at EEC
4-year OLE data: Following treatment in the Phase 1/2a studies, 93% (75/81) of eligible patients continued treatment in the OLEs. As of the 4-year data cutoff, 77% (58/75) of patients remained in these studies. Patients receiving zorevunersen on top of standard anti-seizure medicines (ASMs) continued to experience durable reductions in seizures and ongoing improvements in cognition and behavior. Statistically significant improvements in cognition and behavior were demonstrated at 1, 2, 3 and 4 years of treatment compared to OLE baseline.
Severe seizure analysis: Patients with Dravet syndrome experience frequent, prolonged and refractory seizures. Compared with the general epilepsy population, patients with Dravet syndrome have a significantly increased risk of SUDEP2. Seizures are classified based on severity, with generalized tonic-clonic (GTC), focal-to-bilateral tonic-clonic (focal-to-BTC) and tonic-clonic seizures of unknown origin considered the most severe and correlated with the highest morbidity and mortality in people with epilepsy1. Substantial reductions in GTC and focal-to-BTC seizures were demonstrated through 3 years of the OLEs, compared to Phase 1/2a baseline, in patients treated with zorevunersen on top of standard of care ASMs.
Quality of life analysis: Patients experienced substantial improvements in quality of life through 28 months in the OLEs, compared to Phase 1/2a baseline, as measured by EuroQol Visual Analog Scale (EQ-VAS, a component of the Euro-Qol-5D Youth). EQ-VAS is a validated measure of overall health status ranging from 0 to 100 (worst to best imaginable health) and provides insight into the real-world impact of zorevunersen on patients with Dravet syndrome and their families. “Up to 20% of children and adolescents with Dravet syndrome die before reaching adulthood, and SUDEP is the primary cause,” said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics. “These data are especially meaningful because they show substantial reductions in the severe seizures most strongly correlated with SUDEP and demonstrate continuing improvements in the debilitating neurodevelopmental aspects of the disease. Together with ongoing improvements in quality of life, these data increase our confidence in what zorevunersen may one day deliver for the Dravet community.”
“For patients with a chronic disease like Dravet syndrome, safety and tolerability are critically important,” said Stephanie Fradette, Pharm.D., Head of the Rare Neurology Development Unit at Biogen. “The ongoing open-label extension studies will continue to grow the body of evidence shaping our understanding of zorevunersen’s long-term safety as well as its potential to address the underlying genetic cause of Dravet syndrome and improve outcomes for patients. We look forward to results from the Phase 3 EMPEROR study next year.”
Summary of Zorevunersen Safety Data
Zorevunersen continues to be generally well tolerated, with some patients treated for more than 5 years in the Phase 1/2a and ongoing OLE studies. As of July 31, 2026, more than 930 doses have been administered.Elevated CSF protein lab values occurred in approximately 94% of patients, of which 59% have been classified as a treatment-emergent adverse event. Importantly, no serious or severe clinical manifestations have been associated with CSF protein elevations. There have been no reports of hydrocephalus. About Dravet Syndrome
Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent seizures as well as significant cognitive and behavioral impairments. Most cases of Dravet are caused by mutations in one copy of the SCN1A gene, leading to insufficient levels of NaV1.1 protein in neuronal cells in the brain. Even when treated with the best available anti-seizure medicines (ASMs), up to 57 percent of patients with Dravet syndrome do not achieve ≥50 percent reduction in seizure frequency. Complications of the disease often contribute to a poor quality of life for patients and their caregivers. Developmental and cognitive impairments often include intellectual disability, developmental delays, movement and balance issues, language and speech disturbances, growth defects, sleep abnormalities, disruptions of the autonomic nervous system and mood disorders. Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP; up to 20 percent of children and adolescents with Dravet syndrome die before adulthood due to SUDEP, prolonged seizures, seizure-related accidents or infections3. Dravet syndrome occurs globally and is not concentrated in a particular geographic area or ethnic group. Currently, it is estimated that up to 38,000 people are living with Dravet syndrome in the U.S. (~16,000), UK, EU-4 and Japan4. There are no approved disease-modifying therapies for people living with Dravet syndrome.
About Zorevunersen
Zorevunersen is an investigational antisense oligonucleotide that is designed to treat the underlying cause of Dravet syndrome by increasing functional NaV1.1 protein production in brain cells from the unaffected (wild-type) copy of the SCN1A gene. This highly differentiated mechanism of action aims to reduce seizure frequency beyond what has been achieved with anti-seizure medicines and to improve neurodevelopment, cognition and behavior. Zorevunersen has demonstrated the potential for disease modification and has been granted orphan drug designation by the FDA and the EMA. The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function in the SCN1A gene, and China’s Center for Drug Evaluation has granted zorevunersen Breakthrough Therapy Designation. Stoke has a strategic collaboration with Biogen (Nasdaq: BIIB) to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights. Zorevunersen is currently in clinical development, and its safety and efficacy have not been evaluated by any regulatory authority.
About the Phase 1/2a and Open-Label Extension Studies
Two Phase 1/2a open-label, multicenter studies evaluated the effects of zorevunersen in patients with highly refractory Dravet syndrome ages 2 to 18 years (N=81). Primary endpoints were the safety profile, plasma pharmacokinetics (PK) and exposure in cerebrospinal fluid (CSF) of single and multiple doses of zorevunersen. Secondary endpoints included percentage change from baseline in major motor seizure frequency, overall clinical status (a measure of patients’ overall functioning) and quality of life. The ADMIRAL Phase 1/2a study included an exploratory endpoint to evaluate changes in neurodevelopmental status (cognition & behavior) as measured by Vineland Adaptive Behavior Scales, Third Edition (Vineland-3). The Phase 1/2a studies were completed in November 2023. Following treatment in the Phase 1/2a studies, eligible patients continued treatment with zorevunersen every four months in one of two OLEs. There was at least a 6-month gap between the last dose administered in the Phase 1/2a studies and the first dose administered in the OLEs. The primary endpoints are the safety profile of multiple doses of zorevunersen. Secondary endpoints include PK parameters, percentage change from baseline in major motor seizure frequency, change in overall clinical status, and change from baseline in quality of life. Exploratory endpoints include changes in neurodevelopment status as measured by Vineland-3. Results from the Phase 1/2a and OLE studies were published in The New England Journal of Medicine (NEJM) in March 2026. The OLE studies are ongoing.
About the Phase 3 EMPEROR Study
The Phase 3 EMPEROR Study (NCT06872125) is a global, double-blind, sham-controlled study evaluating the efficacy, safety and tolerability of zorevunersen in children ages 2 to <18 with Dravet syndrome with a confirmed variant in the SCN1A gene not associated with gain-of-function. Stoke completed enrollment in the United States, United Kingdom and Japan in June 2026, and a data readout is anticipated in the third quarter of 2027 to support the submission of a rolling New Drug Application (NDA) to the FDA. Enrollment in Europe completed in August 2026. Enrollment is currently underway in China and is anticipated to complete in the second half of 2026. Participants in EMPEROR are randomized 1:1 to receive either zorevunersen via intrathecal administration or a sham comparator for a 52-week treatment period following an 8-week baseline period. Following the completion of the study treatment period, eligible participants will be offered ongoing treatment with zorevunersen as part of an open-label period of the study. The primary endpoint of the study is percent change from baseline in major motor seizure frequency at week 28 in patients receiving zorevunersen as compared to sham. The key secondary endpoints are the durability of effect on major motor seizure frequency and improvements in behavior and cognition as measured by Vineland-3 subdomains, including expressive communication, receptive communication, interpersonal relationships, coping skills and personal skills. Additional endpoints include safety, Clinician Global Impression of Change (CGI-C), Caregiver Global Impression of Change (CaGI-C) and the Bayley Scales of Infant Development (BSID-IV). For more information, visit https://clinicaltrials.gov/study/NCT06872125.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow us on LinkedIn.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, Instagram, LinkedIn, X, YouTube.
Stoke Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the ability of zorevunersen to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in behavior and cognition at the indicated dosing levels or at all; the potential benefits, safety and efficacy of zorevunersen; the design, timing and expected progress of clinical trials, data readouts, regulatory meetings, regulatory decisions and other presentations; and the potential timing for initiation and completion of the U.S. NDA submission to the FDA. Statements including words such as “plan,” “potential,” “will,” “continue,” “expect,” or similar words and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause Stoke’s results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: Stoke’s ability to advance, obtain regulatory approval and ultimately commercialize its product candidates; that if Biogen were to breach or terminate the collaboration, Stoke would not obtain the anticipated financial or other benefits; the possibility that Stoke and Biogen may not be successful in their development of zorevunersen and that, even if successful, they may be unable to successfully commercialize zorevunersen; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; Stoke’s ability to protect its intellectual property; Stoke’s ability to fund development activities and achieve development goals into 2028; and the other risks and uncertainties described under the heading “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2025, its quarterly reports on Form 10-Q, and the other documents it files with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Stoke undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Biogen Safe Harbor
This news release contains forward-looking statements, including, among others, relating to: the potential clinical effects of zorevunersen; the potential for zorevunersen to improve outcomes for patients with Dravet syndrome; the expected timing of Phase 3 study results; the potential benefits, safety and efficacy of zorevunersen; potential regulatory discussions, applications, submissions and approvals and the timing thereof; the potential treatment of the underlying genetic cause of Dravet syndrome; the anticipated benefits, risks and potential of Biogen's collaboration arrangements with Stoke Therapeutics; the potential of Biogen's commercial business and pipeline programs, including zorevunersen; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.
These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.
These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.
Biogen Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.
References:
Beniczky, S. et al. Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy. Epilepsia. 2025; 1804–1823.Shmuely, S. et al. Mortality in Dravet syndrome: A review, Epilepsy & Behavior. 2016: (Pt A) 69-74.Symonds, J. et al. Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants. Brain. 2021;144(9):2879-2891.Based on Stoke Therapeutics’ preliminary estimates, which scaled annual incidence to prevalence using country-specific live birth rates over the past 85 years and adjusted for Dravet-specific mortality. The estimate is based on incidence rates published by Wu et al., Pediatrics, 2015. Stoke Media & Investor Contacts:
Susan Willson
Vice President, Corporate Communications [email protected]
415-509-8202
Waste Management v poslední seanci vzrostla o 1,22 % na 221,72 USD a překonala S&P 500. Před zveřejněním výsledků trh čeká EPS 2,18 USD a tržby 6,79 miliardy USD.
Waste Management (WM - Free Report) closed at $221.72 in the latest trading session, marking a +1.22% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 1.06%. Meanwhile, the Dow gained 1.18%, and the Nasdaq, a tech-heavy index, added 1.4%.
Shares of the garbage and recycling hauler have depreciated by 2.35% over the course of the past month, underperforming the Business Services sector's gain of 1.35%, and the S&P 500's gain of 2.46%.
Analysts and investors alike will be keeping a close eye on the performance of Waste Management in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $2.18, marking a 10.1% rise compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.79 billion, up 5.34% from the year-ago period.
WM's full-year Zacks Consensus Estimates are calling for earnings of $8.13 per share and revenue of $26.35 billion. These results would represent year-over-year changes of +8.4% and +4.54%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Waste Management. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.06% lower. At present, Waste Management boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Waste Management is at present trading with a Forward P/E ratio of 26.95. This signifies a premium in comparison to the average Forward P/E of 26.39 for its industry.
We can also see that WM currently has a PEG ratio of 2.76. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Waste Removal Services industry was having an average PEG ratio of 2.76.
The Waste Removal Services industry is part of the Business Services sector. This industry currently has a Zacks Industry Rank of 174, which puts it in the bottom 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Progressive (PGR - Free Report) closed at $223.91 in the latest trading session, marking a +1.14% move from the prior day. This change outpaced the S&P 500's 1.06% gain on the day. Elsewhere, the Dow gained 1.18%, while the tech-heavy Nasdaq added 1.4%.
The stock of insurer has risen by 4.05% in the past month, leading the Finance sector's gain of 0.85% and the S&P 500's gain of 2.46%.
Investors will be eagerly watching for the performance of Progressive in its upcoming earnings disclosure. In that report, analysts expect Progressive to post earnings of $3.98 per share. This would mark a year-over-year decline of 1.73%. Alongside, our most recent consensus estimate is anticipating revenue of $23.29 billion, indicating a 4.83% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $17.74 per share and revenue of $92.26 billion, which would represent changes of -2.79% and +6.12%, respectively, from the prior year.
Any recent changes to analyst estimates for Progressive should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.42% increase. Progressive currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Progressive is at present trading with a Forward P/E ratio of 12.48. This valuation marks a premium compared to its industry average Forward P/E of 11.55.
It is also worth noting that PGR currently has a PEG ratio of 2.95. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. PGR's industry had an average PEG ratio of 1.71 as of yesterday's close.
The Insurance - Property and Casualty industry is part of the Finance sector. With its current Zacks Industry Rank of 60, this industry ranks in the top 25% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Akcie společnosti Kinder Morgan v posledním obchodním dni klesly o 1,16 % na 31,60 USD, zatímco index S&P 500 vzrostl o 1,06 %. Za poslední měsíc akcie přidaly 2,73 %.
In the latest close session, Kinder Morgan (KMI - Free Report) was down 1.16% at $31.60. This change lagged the S&P 500's 1.06% gain on the day. Meanwhile, the Dow gained 1.18%, and the Nasdaq, a tech-heavy index, added 1.4%.
The stock of oil and natural gas pipeline and storage company has risen by 2.73% in the past month, lagging the Oils-Energy sector's gain of 4.7% and overreaching the S&P 500's gain of 2.46%.
The investment community will be closely monitoring the performance of Kinder Morgan in its forthcoming earnings report. In that report, analysts expect Kinder Morgan to post earnings of $0.33 per share. This would mark year-over-year growth of 13.79%. Simultaneously, our latest consensus estimate expects the revenue to be $4.49 billion, showing a 8.33% escalation compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.54 per share and a revenue of $18.49 billion, indicating changes of +18.46% and +9.19%, respectively, from the former year.
It is also important to note the recent changes to analyst estimates for Kinder Morgan. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.74% upward. As of now, Kinder Morgan holds a Zacks Rank of #3 (Hold).
Looking at its valuation, Kinder Morgan is holding a Forward P/E ratio of 20.73. This valuation marks a premium compared to its industry average Forward P/E of 20.35.
Also, we should mention that KMI has a PEG ratio of 2.27. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Oil and Gas - Production and Pipelines was holding an average PEG ratio of 1.9 at yesterday's closing price.
The Oil and Gas - Production and Pipelines industry is part of the Oils-Energy sector. This group has a Zacks Industry Rank of 188, putting it in the bottom 24% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Kirby McInerney LLP vyšetřuje OSI Systems kvůli možnému porušení federálních zákonů o cenných papírech po slabších výsledcích za 4. čtvrtletí 2026. Tržby klesly meziročně o 4,1 % na 484,1 milionu USD a akcie po zprávě spadly o 5,21 %.
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against OSI Systems, Inc. (“OSI” or the “Company”) (NASDAQ: OSIS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired OSI securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to learn more about your rights.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On August 20, 2026, OSI reported its fourth quarter 2026 and full-year 2026 financial results, revealing fourth quarter revenue that fell short of analysts’ expectations by 8.5%, with sales falling 4.1% year-on-year to $484.1 million. The Company attributed the revenue shortfall to Security division delivery disruptions caused by conflicts in the Middle East, stating, “these results were affected by the timing of approximately $50 million of planned Security deliveries that moved beyond our June 30th fiscal year-end because of conflict-related delays and site access constraints in the Middle East.” On this news, OSI’s stock price fell $11.36, or 5.21%, to close at $206.73 per share on August 21, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.
If you purchased or otherwise acquired OSI securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Asana, Inc. (ASAN - Free Report) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +11.11%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.1, delivering a surprise of +25%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Asana, which belongs to the Zacks Internet - Software industry, posted revenues of $216.43 million for the quarter ended July 2026, surpassing the Zacks Consensus Estimate by 1.09%. This compares to year-ago revenues of $196.94 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Asana shares have lost about 28.5% since the beginning of the year versus the S&P 500's gain of 12%.
What's Next for Asana?While Asana has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Asana was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.09 on $218.38 million in revenues for the coming quarter and $0.38 on $860.35 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, SailPoint, Inc. (SAIL - Free Report) , has yet to report results for the quarter ended July 2026. The results are expected to be released on September 9.
This company is expected to post quarterly earnings of $0.08 per share in its upcoming report, which represents a year-over-year change of +14.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
SailPoint, Inc. 's revenues are expected to be $310.4 million, up 17.4% from the year-ago quarter.
Guidewire Software oznámila zisk 0,99 USD na akcii a tržby 411,09 milionu USD za čtvrtletí končící v červenci 2026, obojí nad odhady. Zisk i tržby meziročně vzrostly.
Guidewire Software (GWRE - Free Report) came out with quarterly earnings of $0.99 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.84 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +5.32%. A quarter ago, it was expected that this provider of software to the insurance industry would post earnings of $0.79 per share when it actually produced earnings of $0.82, delivering a surprise of +3.8%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Guidewire Software, which belongs to the Zacks Internet - Software industry, posted revenues of $411.09 million for the quarter ended July 2026, surpassing the Zacks Consensus Estimate by 2.20%. This compares to year-ago revenues of $356.57 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Guidewire Software shares have lost about 4.1% since the beginning of the year versus the S&P 500's gain of 12%.
What's Next for Guidewire Software?While Guidewire Software has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Guidewire Software was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.83 on $381.97 million in revenues for the coming quarter and $4.07 on $1.68 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Oddity Tech (ODD - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on September 9.
This online retailer of cosmetics and beauty products is expected to post quarterly earnings of $0.12 per share in its upcoming report, which represents a year-over-year change of -87%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Oddity Tech's revenues are expected to be $174.8 million, down 27.5% from the year-ago quarter.
Guidewire Software uzavřela fiskální rok 2026 s ročními opakujícími se příjmy (ARR) ve výši 1,242 miliardy USD, tedy nad odhadem, díky migracím do cloudu a silné poptávce po AI a cloudových cenových produktech. Cloud ARR vzrostl meziročně o 35 % a tvořil 84 % celkového ARR.
Looking Beyond CrowdStrike? 3 AI Security Stocks Stand OutGuidewire Software NYSE: GWRE closed fiscal 2026 with annual recurring revenue, or ARR, above its guidance range, supported by cloud migrations, low customer attrition and demand for newer artificial intelligence and pricing products.
Chief Executive Officer Mike Rosenbaum said ARR ended the fiscal year at $1.242 billion, up 19% year over year on a constant-currency basis. After a $5 million foreign-exchange adjustment at year-end, ARR was $1.237 billion, Chief Financial Officer Jeff Cooper said. Fully ramped ARR, which reflects the annualized value of customer contracts once fully deployed, rose 22% on a constant-currency basis.
Get Guidewire Software alerts:
Guidewire’s Buyback Could Be the Clue the Sell-Off Is EndingThe company reported 26 core deals in the fourth quarter and 62 for the full fiscal year, covering PolicyCenter, ClaimCenter, BillingCenter or InsuranceNow. Guidewire’s cloud ARR grew 35% year over year and represented 84% of total ARR, Cooper said.
Nationwide migration and product expansion A key fourth-quarter agreement came from Nationwide, which signed a multiyear deal to move its full InsuranceSuite estate to Guidewire Cloud Platform. Nationwide also selected PricingCenter for personal-lines pricing and rating, becoming Guidewire’s first U.S. tier-one PricingCenter customer, according to the company.
Down 20%+, These 3 Software Stocks Are Boosting BuybacksRosenbaum said the Nationwide relationship, which spans more than a decade, validates Guidewire’s ability to support large insurers in the cloud. He added that the PricingCenter deployment is expected to test the product’s capability and scale for other tier-one insurers.
Guidewire closed eight PricingCenter deals during the fourth quarter and 12 for the full year. Other customers selecting or expanding PricingCenter included Capital Insurance Group, Shelter Insurance and Achmea Farm Insurance in Australia. A longstanding customer in Finland became the company’s first existing InsuranceSuite customer in Europe to adopt the product.
President John Mullen said the pricing market is fragmented, with insurers generally using multiple established rating and pricing tools rather than internally developed systems. He said PricingCenter’s integration with PolicyCenter, Advanced Product Designer and Guidewire’s data platform is intended to help insurers make pricing changes more quickly and accurately.
AI products gain commercial traction Guidewire also highlighted early demand for ProNavigator, an AI-driven assistance product embedded in ClaimCenter and PolicyCenter workflows. The company recorded 14 ProNavigator wins in the fourth quarter and 28 for the full year.
Customers adopting ProNavigator included MAPFRE US, Definity, Alfa Insurance and Hollard in Australia. Mullen said customers are using the product for insurance-domain AI capabilities, claims and adjuster experiences, and as an alternative to internally developed tools.
Rosenbaum said ProNavigator’s early momentum was primarily from cross-selling into Guidewire’s installed base. Over time, he said, the product could differentiate Guidewire’s core systems in new customer opportunities, rather than necessarily serving as a standalone entry point.
The company also said developer assistants are now available to customers and partners, while its Qusar release introduced an agentic platform designed to let insurers build AI agents tailored to their existing Guidewire implementations and workflows. Management emphasized that Guidewire intends to support open architectures and integrations with third-party AI systems, while positioning its core platform as a source of structured insurance data and operational context.
Fiscal 2026 revenue, profits and cash flow For fiscal 2026, Guidewire reported total revenue of $1.475 billion, up 23% year over year. Subscription revenue rose 37% to $916 million, while subscription and support revenue increased 33% to $971 million. License revenue declined 7% to $235 million as customers continued transitioning from term licenses to cloud subscriptions. Services revenue increased 23% to $270 million.
Non-GAAP gross profit rose 25% to $990 million, with an overall gross margin of 67%. Subscription and support gross margin expanded four percentage points to 74.5%. Non-GAAP operating income increased 63% to $340 million. Operating cash flow grew 30% to $390 million. Guidewire ended the period with $1.2 billion in cash equivalents and investments. The company repurchased $606 million of stock during fiscal 2026, representing 4.1 million shares at an average price of $148.41 per share. Rosenbaum also pointed to gross ARR attrition of less than 1.5% across all ARR and less than 1% among core-systems customers.
Cooper said Guidewire had 105 customers with fully ramped ARR above $5 million at fiscal year-end, compared with 86 at the end of fiscal 2025.
Fiscal 2027 outlook For fiscal 2027, Guidewire forecast ARR of $1.45 billion to $1.46 billion, representing 18% constant-currency growth at the midpoint. More than half of the net new ARR included in the outlook is already under contract with defined ramp dates, Cooper said.
The company expects total revenue of $1.707 billion to $1.727 billion, including subscription and support revenue of $1.240 billion to $1.246 billion. Guidewire expects license revenue of about $189 million and services revenue of about $285 million.
Guidewire forecast non-GAAP operating income of $403 million to $423 million, GAAP operating income of $197 million to $217 million, and operating cash flow of $445 million to $465 million. It expects subscription and support gross margin of 75% to 76% and total gross margin of 67% to 68%.
For the first quarter, the company projected ARR of $1.253 billion to $1.259 billion and subscription and support revenue of $279 million to $283 million. Cooper said first-quarter subscription and support margin should be about 77%, aided by roughly $4 million in cloud-infrastructure-provider credits, while services margin is expected to be around break-even due in part to the timing of fixed-fee services engagements.
Cooper also said Chief Accounting Officer David Pedersen plans to retire in early November.
About Guidewire Software (NYSE:GWRE)Guidewire Software, Inc develops software products and cloud services for property and casualty (P&C) insurance carriers. Headquartered in San Mateo, California, the company's offerings are designed to help insurers manage the core functions of their business—policy administration, billing and claims—while supporting digital engagement, analytics and operational modernization.
Guidewire's core product portfolio is commonly known as the InsuranceSuite, which includes PolicyCenter for policy administration, BillingCenter for billing and receivables, and ClaimCenter for claims management.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Guidewire Software Right Now?Before you consider Guidewire Software, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guidewire Software wasn't on the list.
While Guidewire Software currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
EPC Power's Intelligent Power Conversion Solutions Directly Address the Fundamental Challenges of an Aging U.S. Power Grid Supporting the Energy Demand Supercycle and the AI Era
, /PRNewswire/ -- EPC Power Corp. ("EPC Power"), a leading North American designer and manufacturer of high-performance, software-defined power conversion solutions for data centers, utility-scale energy storage, and microgrids, today announced it has entered into a definitive agreement to be acquired by Flex (NASDAQ: FLEX) for $4.4 billion. The transaction is subject to customary closing conditions, including the receipt of required regulatory approvals, and is expected to close in the fourth quarter of 2026. Building on the two companies' existing collaboration, EPC Power will become, upon closing, a business within Flex's Cloud and Power Infrastructure segment.
The transaction brings EPC Power's differentiated power conversion technology platform to Flex's broad portfolio of power and thermal management technologies for mission-critical applications. EPC Power's next-generation 800-volt data center power architectures, including digital rectifiers and solid-state transformers, enable more efficient power delivery for higher-density AI infrastructure and extend leadership with Flex into an integrated grid-to-chip portfolio. The combined company is positioned to help solve one of the most pressing challenges facing the technology and energy industries today: delivering the fast, resilient and secure power that AI data centers need while supporting stable grid operations amid a generational surge in power demand.
"What we accomplished over the last four years demonstrates the power of strong partnerships and a shared commitment to innovation. Together with Goldman Sachs Alternatives and Cleanhill Partners, EPC Power emerged as a U.S. technology leader in power conversion solutions that enable the next generation of data centers, AI computing, and grid modernization. We expanded our domestic manufacturing footprint nearly tenfold, strengthening America's industrial base and reinforcing the critical role of U.S. innovation in powering the future economy. This is only the beginning of what EPC Power can accomplish," said Jim Fusaro, Chief Executive Officer of EPC Power.
"This is a landmark moment for EPC Power and every colleague who helped build this company. When we founded EPC Power, we set out to solve the hardest problems in power electronics, and our partnership with Goldman Sachs Alternatives and Cleanhill Partners enabled us to solve those problems for mission-critical infrastructure globally," added Devin Dilley, Co-Founder, President and Chief Innovation Officer of EPC Power.
Solving the Binding Constraint on AI Infrastructure
Power availability has become the gating factor for data center growth. As AI workloads drive unprecedented increases in power density, resilience and control requirements, operators must address speed-to-power and load volatility, where the rapid, large-swing power draw of AI training and inference clusters can destabilize the local grid.
EPC Power's technology is purpose-built for these conditions. The company's solutions, including its Agile Grid Forming™ technology, deliver performance and reliability that enables on-site energy storage, microgrid and grid-support configurations for data centers, which allow operators to energize capacity faster and ride through grid instability. Grid operators and utilities benefit from stronger reliability and power quality across their networks.
"We are immensely proud of our partnership with Jim, Devin and the EPC Power team that saw the company launch new product platforms, increase domestic U.S. manufacturing and partner with customers to solve novel challenges in AI power architecture. EPC Power plays a critical role in supporting grid reliability and speed to power during a period of growing concerns around energy security. We wish Flex and the EPC team continued success during their stage of growth," said Alexander Mass, Global Co-Head of Energy Transition Investing within Private Equity at Goldman Sachs Alternatives.
"As grid resilience and data center power demand have converged into one of the defining challenges of the next decade, it has been a privilege to support EPC Power's operational and commercial scale-up into a global platform positioned at the center of those megatrends," added Eddie Sigman, Investor within Private Equity at Goldman Sachs Alternatives.
"We first invested in EPC Power in 2021 because we believed power conversion would become a critical enabling technology as renewable generation, grid modernization and digital infrastructure converged. That conviction came well before the extraordinary growth in power demand driven by AI. Since then, we have had the privilege of working closely with Jim, Devin and the EPC team as the company grew, expanded its U.S. manufacturing footprint and created high-quality jobs in the U.S. We are proud to have supported EPC from an early stage and, in its next phase, alongside Goldman Sachs Alternatives as the business entered a new period of growth. Seeing what the team has built over the past five years has been incredibly rewarding, and we believe Flex is the right partner for EPC's next chapter," said Ash Upadhyaya and Rakesh Wilson, Managing Partners at Cleanhill Partners.
Goldman Sachs & Co. LLC. and J.P. Morgan Securities LLC served as financial advisors, and Vinson & Elkins LLP served as legal counsel, to EPC Power and its controlling shareholders Goldman Sachs Alternatives and Cleanhill Partners.
About EPC Power
EPC Power Corp. (EPC Power) is a power solutions platform that develops high-performance power conversion systems for mission-critical applications, including data centers, utility-scale energy storage, and microgrids. EPC Power's solutions are designed to deliver reliable, resilient, and secure energy for demanding applications, including AI-driven workloads and grid stability use cases supported by EPC Power's Agile Grid Forming™ technology. Visit EPCPower.com for more information.
About Flex
Flex (Reg. No. 199002645H) is the manufacturing partner of choice that helps leading brands design, build, and manage products that improve the world. With a global footprint spanning 30 countries, Flex delivers advanced manufacturing and supply chain solutions, innovative products and technology, and lifecycle services that support customers from concept to scale. In the AI era, Flex is helping customers accelerate data center deployment by solving power, heat, and scale challenges through cutting-edge power and cooling technology and scalable IT infrastructure solutions. For information about Flex's intent to spin off its Cloud and Power Infrastructure portfolio, visit: https://flex.com/transaction-resources
About Private Equity at Goldman Sachs Alternatives
Goldman Sachs (NYSE: GS) is one of the leading investors in alternatives globally, with over $706 billion in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives including private equity, growth equity, venture capital, private credit, real estate, infrastructure, sustainability, and hedge funds. Clients access these solutions through direct strategies, customized partnerships, and open-architecture programs.
The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets.
The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world's leading institutions, financial advisors and individuals. Goldman Sachs has more than $4.0 trillion in assets under supervision globally as of June 30, 2026.
Established in 1986, Private Equity at Goldman Sachs Alternatives has invested over $75 billion since inception. The business combines a global network of relationships, unique insight across markets, industries and regions, and the worldwide resources of Goldman Sachs to build businesses and accelerate value creation across its portfolios.
Follow us on LinkedIn
About Cleanhill Partners
Cleanhill Partners is a private equity firm focused on energy transition and digital infrastructure. The firm invests in companies across power generation, energy storage, grid modernization, domestic manufacturing and related technologies that support the growing demand for reliable power.
Cleanhill works closely with management teams to help companies scale and build long-term value. The firm is led by investors and operators with more than two decades of experience across. For more information, visit www.cleanhillpartners.com.
SoundHound AI ve 2. čtvrtletí zvýšila tržby o 45 % na 61,9 milionu USD a zvedla spodní hranici celoročního výhledu tržeb na 230 až 260 milionů USD. Akcie ale zůstávají vysoce spekulativní kvůli ztrátě a chystané akvizici LivePerson.
With about 40% short interest, SoundHound AI (SOUN -0.59%) is one of the most shorted stocks in the market. The company has been growing its revenue quickly, but a pending merger with troubled LivePerson (LPSN +0.00%) has investors betting against the stock. However, heavy short interest is a double-edged sword.
If a stock has high short interest, there is usually a bearish case to be made against it. In the case of SoundHound AI, its merger with LivePerson will bring considerable debt and a business currently in decline. There is also a good chance that SoundHound AI will seek a future equity raise to pay off the debt it is taking on as part of the deal, as it has stated it will work to quickly retire the debt through a combination of cash and stock.
The flip side is that heavily shorted stocks can see huge short squeezes if they can prove the skeptics wrong. With LivePerson, SoundHound AI is gaining access to a large, established, albeit declining, customer base, especially in call centers and the customer service space.
Its goal will be to retain these customers and switch them to its more comprehensive and higher-priced AI voice technology and agentic AI platform. If the company can stabilize churn and upsell customers, this deal could be a huge boon for this growth stock.
Image source: The Motley Fool.
SoundHound AI's core business, meanwhile, continues to perform well, and it's already shown it can integrate acquisitions well. Its earlier purchase of Amelia and its virtual agents helped it expand into new market verticals and provided key technology for its new voice-native agentic AI orchestration platform, OASYS.
The company has said that the launch of OASYS has increased excitement and accelerated deals, and that it is winning in demos, RFPs (requests for proposals), and pilots. The platform's ability to build AI agents and self-improve has been a big selling point, and it has been seeing pilots convert to large implementations at a record pace. Management noted that the platform has seen rapid adoption across verticals since its May launch, including a large eight-figure deal signed in less than 90 days after the initial demo.
Overall for Q2, SoundHound AI saw its revenue climb 45% to $61.9 million. However, the company does remain unprofitable, with an adjusted loss of $0.02 and negative adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $9.6 million. Its gross margin rose 610 basis points year over year to 45.1%, while its adjusted gross margins were flat year over year at 58.4%. It said acquisitions continued to have a temporary impact on its gross margins and that its goal is to still exceed 70% in the future.
Looking ahead, the company raised the low end of its full-year revenue guidance to $230 million to $260 million. That's up from a prior outlook of $225 million to $260 million. It is expecting its acquisition of LivePerson to close by the end of the year. If it does, it is projected to generate at least $350 million of revenue in 2027.
Premium Feature
Moneyball Superscore
68/100
Today's Change
(
-0.59
%) $
-0.04
Current Price
$
6.74
SoundHound AI's stock has struggled over the past year, with its shares cut in half. However, the stock is still not cheap, trading at a forward price-to-sales (P/S) ratio of over 12 times current-year estimates. With the company not profitable and burning cash, that alone makes it a more speculative bet. The acquisition of LivePerson, meanwhile, adds some additional risk.
That said, the company has shown it can do a good job integrating acquisitions, and it has a huge opportunity with OASYS, both with existing customers and the ones it is acquiring from LivePerson.
Despite the huge short interest, I think investors can place a small speculative bet that SoundHound AI can pull this deal off, given the early momentum it has been seeing with OASYS.
Smith & Wesson Brands zveřejnila výsledky za 1. čtvrtletí fiskálního roku 2027. V hovoru upozornila, že část údajů je ne-GAAP a EPS znamená plně zředěné EPS.
Smith & Wesson Brands, Inc. (SWBI) Q1 2027 Earnings Call September 3, 2026 5:00 PM EDT
Company Participants
Kevin Maxwell - Senior VP, General Counsel, Chief Compliance Officer & Secretary
Mark Smith - President, CEO & Director
Deana McPherson - Executive VP, CFO, Treasurer & Assistant Secretary
Conference Call Participants
Alex Ewig
Presentation
Operator
Good day, everyone, and welcome to Smith & Wesson Brands, Inc. First Quarter Fiscal 2027 Financial Results Conference Call. This call is being recorded.
At this time, I would like to turn the call over to Kevin Maxwell, Smith & Wesson's General Counsel, who will give us information about today's call. Thank you. You may begin.
Kevin Maxwell
Senior VP, General Counsel, Chief Compliance Officer & Secretary
Thank you and good afternoon. Our comments today may contain forward-looking statements. Our use of the words anticipate, project, estimate, expect, intend, believe, and other similar expressions are intended to identify forward-looking statements. Forward-looking statements may also include statements on topics such as our product development, strategies, market share, demand, consumer preferences, inventory conditions for our products, growth opportunities and trends, and industry conditions in general.
Forward-looking statements represent our current judgment about the future and are subject to risks and uncertainties that could cause our actual results to differ materially from those expressed or implied by our statements today. These risks and uncertainties are described in our SEC filing, which are available on our website, along with a replay of today's call. We have no obligation to update forward-looking statements.
We reference certain non-GAAP financial results. Reconciliations of GAAP financial measures to non-GAAP financial measures can be found in our SEC filing and in today's earnings press release, each of which is available on our website. Also, when we reference EPS, we are always referencing fully diluted EPS, and any reference to EBITDA is
